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Abstract
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) of the
European Food Safety Authority (EFSA) was requested to evaluate the genotoxic potential of 26
flavouring substances from subgroup 2.7 of FGE.19 in Flavouring Group Evaluation (FGE) 213. In the
first version of FGE.213 the Panel concluded, based on available genotoxicity data, that a concern
regarding genotoxicity could be ruled out for 11 substances [FL-nos: 07.047, 07.056, 07.057, 07.075,
07.076, 07.080, 07.117, 07.118, 07.119, 07.120 and 07.168], but for the remaining 15 substances in
subgroup 2.7 further genotoxicity data were required. Based on new submitted genotoxicity data, the
Panel concluded in FGE.213Rev1 that the concern regarding genotoxicity could be ruled out for 13
substances in subgroup 2.7 [FL-nos: 02.106, 07.008, 07.010, 07.041, 07.083, 07.089, 07.108, 07.109,
07.127, 07.136, 07.200, 07.224 and 09.305] but not for maltol [FL-no: 07.014] and maltyl isobutyrate
[FL-no: 09.525]. In FGE.213Rev2, new data on maltol were considered and the Panel concluded that
for maltol [FL-no: 07.014] and maltyl isobutyrate [FL-no: 09.525] in food the concern for genotoxicity
could be ruled out. Moreover, the Panel reconsidered the available data on p-mentha-1,4(8)-dien-3-
one [FL-no: 07.127], based on new data on the structurally related substance pulegone, and
concluded that additional genotoxicity data are needed to rule out the concern for genotoxicity of p-
mentha-1,4(8)-dien-3-one [FL-no: 07.127].
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Summary
Following a request from the European Commission, the EFSA Panel on Food Contact Materials,
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion on the
implications for human health of chemically defined flavouring substances used in or on foodstuffs in
the Member States. In particular, the Scientific Panel was asked to evaluate flavouring substances
using the procedure referred to in Commission Regulation EC No 1565/2000 (hereafter ‘the
Procedure’).
The Flavouring Group Evaluation (FGE) 213 concerns 26 substances, corresponding to subgroup 2.7
of FGE.19. Twenty-three of the substances are α,β-unsaturated alicyclic ketones [Flavour Information 
System (FL)-nos: 07.008, 07.010, 07.014, 07.041, 07.047, 07.056, 07.057, 07.075, 07.076, 07.080,
07.083, 07.089, 07.108, 07.109, 07.117, 07.118, 07.119, 07.120, 07.127, 07.136, 07.168, 07.200 and
07.224] and three are precursors for such ketones [FL-nos: 02.106, 09.305 and 09.525].
In the first version of FGE.213 the Panel concluded that the genotoxicity concern for ethyl maltol [FL-
no: 07.047], 3-ethylcyclopentan-1,2-dione [FL-no: 07.057] and the nine structurally related
substances [FL-nos: 07.117, 07.118, 07.119, 07.120, 07.056, 07.168, 07.075, 07.076 and 07.080]
could be ruled out and the 11 substances could accordingly be evaluated through the Procedure.
For maltol [FL-no: 07.014], a micronucleus assay after oral application was required in addition to an
in vivo comet assay in order to clarify the genotoxic potential. The outcome would also be applicable
to maltyl isobutyrate [FL-no: 09.525].
The remaining 13 substances (including two precursors of a ketone) [FL-nos: 02.106, 07.008, 07.010,
07.041, 07.083, 07.089, 07.108, 07.109, 07.127, 07.136, 07.200, 07.224 and 09.305] could not be
evaluated through the Procedure. Accordingly, additional data on genotoxicity were required for
representatives of these 13 substances.
The Flavour Industry informed that it no longer supports the representative flavouring substance,
piperitenone oxide [FL-no: 16.044], for which the Panel requested additional data. In FGE.213Rev1,
one additional substance has been included in subgroup 2.7, tr-1-(2,6,6-trimethyl-1-cyclohexen-1-
yl)but-2-en-1-one [FL-no: 07.224], which is structurally related to the other substances for which the
genotoxic potential could not be ruled out.
In FGE.213Rev1, the Panel evaluated the new data submitted by the Flavour Industry in response to
the data request presented in FGE.213. Based on these new data, the Panel concluded that the
genotoxicity concern could be ruled out for the representative substances β-ionone [FL-no: 07.008], 
β-damascone [FL-no: 07.083], nootkatone [FL-no: 07.089], 2,6,6-trimethylcyclohex-2-en-1,4-dione 
[FL-no: 07.109] and the nine substances that they represent [FL-nos: 02.106, 07.010, 07.041, 07.108,
07.127, 07.136, 07.200, 07.224 and 09.305].
In the case of maltol, positive results were observed in an in vitro micronucleus assay in human
peripheral blood lymphocytes and in an in vivo micronucleus assay in mouse bone marrow after
intraperitoneal application. Maltol was also tested in rats (administered by gavage) in a combined
bone marrow micronucleus assay and comet assay in liver. Both tests showed negative results, but no
clinical signs and no bone marrow toxicity were observed. To investigate the systemic exposure,
plasma bioanalysis was performed, but results were inconsistent. Owing to the intended use of maltol
as a food-flavouring agent, the in vivo study performed with administration of maltol by gavage is
considered more relevant than the study performed by intraperitoneal application. Therefore, the
Panel concluded in Revision 1 of this FGE that for maltol [FL-no: 07.014] and maltyl isobutyrate [FL-
no: 09.525] the concern for genotoxicity could not be ruled out.
The Flavour Industry has submitted a new plasma bioanalysis for maltol, which is evaluated in the
present revision of FGE.213 (FGE.213Rev2). The Panel considered this new plasma bioanalysis and
concluded that it seems justifiable to assume that animals were systemically exposed to maltol and
that the bone marrow was exposed in the in vivo micronucleus assay. Therefore, the negative result
of the in vivo micronucleus assay can be considered reliable and, accordingly, the concern for
genotoxicity for maltol [FL-no: 07.014] and for maltyl isobutyrate [FL-no: 09.525] in food is ruled out;
both substances were evaluated by JECFA before 2000 and no EFSA consideration is required.
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Moreover, the Panel reconsidered the available data on p-mentha-1,4(8)-dien-3-one [FL-no: 07.127],
based on new data on the structurally related substance pulegone and concluded that additional
genotoxicity data are needed to rule out the concern for genotoxicity on p-mentha-1,4(8)-dien-3-one
[FL-no: 07.127].
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1. Introduction
Background and Terms of Reference as provided by the requestor1.1.
The use of flavourings is regulated under Regulation (EC) No 1334/20081 of the European Parliament
and Council of 16 December 2008 on flavourings and certain food ingredients with flavouring
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and
approval are required for flavouring substances.
The Union List of flavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20122. The list contains flavouring substances for which the scientific
evaluation should be completed in accordance with Commission Regulation (EC) N° 1565/2000.
On 10 April 2014 the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing
Aids adopted an opinion on Flavouring Group Evaluation 213, Revision 1 (FGE.213Rev1):
Consideration of genotoxic potential for α,β-unsaturated alicyclic ketones and precursors from 
chemical subgroup 2.7 of FGE.19.3
The Panel concluded that, for maltol [FL-no: 07.014] and for maltyl isobutyrate [FL-no: 09.525] the
Panel’s concern with respect to genotoxicity could not be ruled out and subsequently additional data
are requested. In particular it was pointed out that the data provided to prove systemic availability
were considered inconclusive due to the inconsistency of the data.
On 6 January 2015 the applicant has submitted additional data on the representative substance maltol
[FL-no: 07.014] in response to this EFSA evaluation. This additional data regards a study intended to
look at systemic exposure of rats following oral administration of this substance, using the same
dosing regimen employed in the combined micronucleus and comet test previously submitted.
Terms of Reference as provided by the European Commission
The European Commission requests the European Food Safety Authority (EFSA) to evaluate this new
information and, depending on the outcome, proceed to the full evaluation on this flavouring
substance in accordance with Commission Regulation (EC) N° 1565/20004.
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and certain
food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50
2 EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the
list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council,
introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing
Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1-161
3 EFSA Journal 2014;12(2):3587.
4 Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16
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2. Data and Methodologies
History of the evaluation of FGE.19 substances2.1.
Flavouring Group Evaluation (FGE) 19 (FGE.19) contains 360 flavouring substances from the European
Union (EU) Register being α,β-unsaturated aldehydes or ketones and precursors which could give rise 
to such carbonyl substances via hydrolysis and/or oxidation (EFSA, 2008a).
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA, 
2008a). The Panel noted that there were limited genotoxicity data on these flavouring substances but
that positive genotoxicity studies were identified for some substances in the group.
The α,β-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity 
(EFSA, 2008a). In an attempt to decide which of the substances could go through the Procedure, a
(quantitative) structure–activity relationship ((Q)SAR) prediction of the genotoxicity of these
substances was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE
Models and ISS-Local Models, (Gry et al., 2007)).
The Panel noted that for most of these models internal and external validation has been performed,
but considered that the outcome of these validations was not always extensive enough to appreciate
the validity of the predictions of these models for these α,β-unsaturated carbonyls. Therefore, the 
Panel considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and decided
not to take substances through the procedure based on negative (Q)SAR predictions only.
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva,
2007a, b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; Nikolov et al., 2007) and the fact
that there are available data on genotoxicity, in vitro and in vivo, as well as data on carcinogenicity for
several substances. Based on these data the Panel decided that 15 subgroups (1.1.1, 1.2.1, 1.2.2,
1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 2008b) could not be evaluated
through the Procedure because of concerns with respect to genotoxicity. Corresponding to these
subgroups, 15 Flavouring Group Evaluations (FGEs) were established: FGE.200, 204, 205, 206, 207,
208, 209, 211, 215, 219, 221, 222, 223, 224 and 225.
For 11 subgroups the Panel decided, based on the available genotoxicity data and (Q)SAR predictions,
that a further scrutiny of the data should take place before requesting additional data from the
Flavour Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203, 210, 212,
213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218 it was concluded that a
genotoxic potential could be ruled out and accordingly these substances will be evaluated using the
Procedure. For all or some of the substances in the remaining FGEs, FGE.201, 203, 210, 212, 213,
216, 217 and 220 the genotoxic potential could not be ruled out.
To ease the data retrieval of the large number of structurally related α,β-unsaturated substances in 
the different subgroups for which additional data are requested, EFSA worked out a list of
representative substances for each subgroup (EFSA, 2008c). Likewise, an EFSA genotoxicity expert
group has worked out a test strategy to be followed in the data retrieval for these substances (EFSA,
2008b).
The Flavour Industry has been requested to submit additional genotoxicity data according to the list of
representative substances and test strategy for each subgroup.
The Flavour Industry has now submitted additional data and the present FGE concerns the evaluation
of these data requested on genotoxicity.
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History of the evaluation of the substances belonging to FGE.2132.2.
In the EFSA Opinion ‘List of α,β-unsaturated aldehydes and ketones representative of FGE.19 
substances for genotoxicity testing’ (EFSA, 2008c), representative flavouring substances have been
selected for FGE.19 subgroup 2.7, corresponding to FGE.213.
In the first scientific opinion on FGE.213 (EFSA, 2009), the Panel concluded that, based on the data
available, the concern with respect to genotoxicity could be ruled out for 11 substances [FL-nos:
07.047, 07.056, 07.057, 07.075, 07.076, 07.080, 7.117, 07.118, 07.119, 07.120 and 07.168]. Nine of
these substances have been evaluated by the Joint Food and Agriculture Organization of the United
Nations (FAO)/World Health Organization (WHO) Expert Committee on Food Additives (JECFA) before
2000 to be of no safety concern and, in accordance with Commission Regulation (EC) No 1565/2000,
no further consideration is requested. The remaining two substances, ethyl maltol [FL-no: 07.047] and
2-hydroxypiperitone [FL-no: 07.168], were evaluated in FGE.83Rev1 (EFSA CEF Panel, 2010) and
FGE.11Rev2 (EFSA CEF Panel, 2011), respectively, using the Procedure.
For maltol [FL-no: 07.014], the Panel requested a combined in vivo micronucleus and comet assay in
order to clarify the genotoxic potential. The outcome would also be applicable to maltyl isobutyrate
[FL-no: 09.525].
For the remaining 13 substances [FL-nos: 02.106, 07.008, 07.010, 07.041, 07.083, 07.089, 07.108,
07.109, 07.127, 07.136, 07.200, 07.224 and 09.305] additional data on genotoxicity were required for
the representative substances, according to the Opinion of the CEF Panel on the ‘Genotoxicity Test
Strategy for Substances Belonging to Subgroups of FGE.19’ (EFSA, 2008b).
In FGE.213 Revision 1 (FGE.213Rev1) the Panel evaluated additional genotoxicity data submitted by
the Flavouring Industry (IOFI, 2012, 2013) in response to a data request presented in FGE.213 (EFSA,
2009).
The new data submitted concerned five of the original six representative substances requested by the
Panel (EFSA, 2008c), namely β-ionone [FL-no: 07.008], maltol [FL-no: 07.014], β-damascone 
[07.083], nootkatone [FL-no: 07.089] and 2,6,6-trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109]
(Table 1).
The Flavour Industry informed that it no longer supports the representative flavouring substance,
piperitenone oxide [FL-no: 16.044], for which the Panel requested additional data. However, since
piperitenone oxide was a self-representative substance, this did not affect the evaluation of the
remaining substances in FGE.213Rev1.
In FGE.213Rev1, one additional substance was included in subgroup 2.7, tr-1-(2,6,6-trimethyl-1-
cyclohexen-1-yl)but-2-en-1-one [FL-no: 07.224], which is structurally related to the other substances
for which the genotoxic potential could not be ruled out.
In FGE.213Rev1, the Panel concluded that the in vitro and in vivo genotoxicity data for the selected
representative substances β-ionone [FL-no: 07.008], β-damascone [FL-no: 07.083], nootkatone [FL-
no: 07.089] and 2,6,6-trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109] do not indicate a genotoxic
potential. Therefore, these substances, and the nine substances that they represent [FL-no: 02.106,
07.010, 07.041, 07.108, 07.127, 07.136, 07.200, 07.224 and 09.305] could be evaluated through the
Procedure.
During the evaluation of p-mentha-1,4(8)-dien-3-one [FL-no: 07.127], using the Procedure (in
FGE.57Rev1), the Panel noted that the chemical structure of p-mentha-1,4(8)-dien-3-one [FL-no:
FGE Adopted by
EFSA
Link No. of
Substances
FGE.213 27 November
2008
http://www.efsa.europa.eu/en/efsajournal/pub/879.htm 26
FGE.213Rev1 10 April 2014 http://www.efsa.europa.eu/it/efsajournal/pub/3661.htm 26
FGE.213Rev2 09 September
2015
http://www.efsa.europa.eu/it/efsajournal/pub/4244.htm 26
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07.127] is actually more closely related to the structure of pulegone (Table 2) than to the structures
used for the read-across approach in FGE.213Rev1. New information (NTP, 2011) was found on
genotoxicity and carcinogenicity of pulegone, from which additional data are expected to be provided
by the applicant. The data available, at present, on pulegone and on the structurally related p-
mentha-1,4(8)-dien-3-one [FL-no 07.127] do not rule out the concern for genotoxicity and
carcinogenicity. Therefore, the genotoxicity of p-mentha-1,4(8)-dien-3-one [FL-no: 07.127] will be
reconsidered based on additional data.
For maltol [FL-no: 07.014], a combined bone marrow micronucleus test and comet assay in rats
(Beevers, 2013a) was evaluated by the Panel in FGE.213Rev1. The results of the micronucleus test
showed that there were no statistically significant increases in micronucleus frequency for any dose
group after oral treatment with maltol when compared with the vehicle control group. The comet
assay did not reveal cytotoxicity, necrosis or apoptosis in the hepatocytes as assessed by cloud and
halo analysis, and the groups treated with maltol showed mean percentage tail intensities and tail
moments that were similar to vehicle controls and fell within historical control ranges.
The Panel noted that, at the dose levels selected, no clinical signs and no bone marrow toxicity were
observed in any animal in the maltol-treated groups, which may reflect the possibility that the bone
marrow and the liver were not exposed. Therefore, plasma analysis for proof of exposure was
requested. Analysis of maltol in plasma was performed using a gas chromatography with mass
selective detection (GC–MSD) method. Results showed marked inconsistencies among animals and
between sampling times. The Panel concluded that negative findings observed in the combined bone
marrow micronucleus test and comet assay in the liver of treated rats could not rule out the concern
for genotoxicity of maltol since the data provided to prove systemic availability were considered
inconclusive due to the inconsistency of the data.
Following the Panel’s conclusion in FGE.213Rev1, the Flavour Industry has submitted a new plasma
analysis (Beevers, 2015) performed on the same strain of rats and using the same dosing regimen of
the combined micronucleus test and comet assay (Beevers, 2013a). These new data are evaluated in
this revision of FGE.213, FGE.213Rev2.
The new data provided show that detectable levels of maltol were found in all plasma samples
isolated at 0.5, 1 and 2 hours after dosing. Peak plasma levels of maltol were seen in the majority of
animals at 0.5 hours after dose administration. The concentration of maltol detected in plasma was
different between the animals of 2 separate cages and the authors of the study did not identify any
technical reasons that could account for this difference. The new data submitted are described and
evaluated in Section 3 of the present revision. Sections 2.4 and 2.5 report the same information that
was present in FGE.213 and FGE.213Rev1, respectively.
Table 1: Representative substances for subgroup 2.7 of FGE.19
FL-no
JECFA-no EU Register name Structural formula Comments
07.008
389
β-Ionone In vitro assays in bacteria and
mammalian cells submitted
07.014
1480
Maltol In vitro assays in bacteria and
mammalian cells and an in vivo
combined comet and micronucleus
assay submitted
07.083
384
β-Damascone 
O In vitro assays in bacteria and
mammalian cells and an in vivo
combined comet and micronucleus
assay submitted
07.089
1398
Nootkatone In vitro assays in bacteria and
mammalian cells submitted
O
O
O
OH
O
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FL-no
JECFA-no EU Register name Structural formula Comments
07.109
1857
2,6,6-Trimethylcyclohex-2-en
1,4-dione
In vitro assays in bacteria and
mammalian cells submitted
16.044
1574
Piperitenone oxide No longer supported by the Flavour
Industry and no data submitted
Table 2: Supporting substance for subgroup 2.7 of FGE.19
FL-no
JECFA-no Substance name Structural formula Comments
Not in
Register
753
Pulegone Additional in vitro and in vivo data
(NTP, 2011)
Presentation of the substances in flavouring group evaluation 2132.3.
2.3.1. Description
The Flavouring Group Evaluation 213 (FGE.213) concerned 26 substances (Table 4), corresponding to
subgroup 2.7 of FGE.19. Twenty-three of the substances are α,β-unsaturated alicyclic ketones [FL-
nos: 07.008, 07.010, 07.014, 07.041, 07.047, 07.056, 07.057, 07.075, 07.076, 07.080, 07.083,
07.089, 07.108, 07.109, 07.117, 07.118, 07.119, 07.120, 07.127, 07.136, 07.168, 07.200 and 07.224]
(one substance [FL-no 16.044] is no longer supported by the Flavour Industry and one new substance
[FL-no 07.224] has been included in Revision 1) and three are precursors for such ketones [FL-nos:
02.106, 09.305 and 09.525]. Two of these substances [FL-nos: 02.106 and 09.305] are precursors of
the ketone β-ionone [FL-no: 07.008] and one [FL-no: 09.525] is a precursor of the ketone maltol [FL-
no: 07.014]. Ten of the ketones have the possibility for keto–enol tautomerism [FL-nos: 07.056,
07.057, 07.075, 07.076, 07.080, 07.117, 07.118, 07.119, 07.120 and 07.168]. Based on experimental
evidence for other diketones it is anticipated that the enol is the predominant form.
Twenty-two of the substances in FGE.213 (including the new substance [FL-no 07.224], excluding
[FL-no 16.044]) have formerly been evaluated by the JECFA (JECFA, 1999, 2001, 2006a, b, 2009a), a
summary of their current evaluation status by the JECFA is given in Table 5.
As the α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA, 
2008a) the available data on genotoxic or carcinogenic activity for the 26 unsaturated alicyclic ketones
and precursor in subgroup 2.7 will be considered in this FGE.
The Panel has also taken into consideration the outcome of the predictions from five selected (Q)SAR
models (Benigni and Netzeva, 2007a; Gry et al., 2007; Nikolov et al., 2007) on 22 ketones [FL-nos:
07.008, 07.010, 07.014, 07.041, 07.047, 07.056, 07.057, 07.075, 07.076, 07.080, 07.083, 07.089,
07.108, 07.109, 07.117, 07.118, 07.119, 07.120, 07.127, 07.136, 07.168 and 07.200]. The 22 ketones
and their (Q)SAR predictions are shown in Table 6.
O
O
O
O
O
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Data evaluated by the Panel in FGE.21352.4.
2.4.1. (Q)SAR predictions
In Table 6 the outcomes of the (Q)SAR predictions for possible genotoxic activity in five in vitro
(Q)SAR models (ISS-Local Model–Ames test, DTU–NFI-MULTICASE–Ames test, Chromosomal
aberration test (using Chinese hamster ovary (CHO) cells), Chromosomal aberration test (using
Chinese hamster lung (CHL) cells) and Mouse lymphoma test) are presented.
Maltol [FL-no: 07.014], ethyl maltol [FL-no: 07.047] and nootkatone [FL-no: 07.089] were predicted
positive with the MultiCASE model on chromosomal aberrations in CHL cells. All other predictions were
negative or the substances were out of domain.
2.4.2. Genotoxicity studies
In subgroup 2.7 there are studies available for four substances. For maltol [FL-no: 07.014] eight in
vitro and three in vivo studies have been evaluated. For ethyl maltol [FL-no: 07.047] two in vitro and
one in vivo study were evaluated. Two in vitro studies concerning β-ionone [FL-no: 07.008] and one 
in vitro study for 3-methylcyclopentan-1,2-dione [FL-no: 07.056] were evaluated.
Study validation and results are presented in Tables 7 and 8.
In studies that were considered valid, the following results were obtained:
• Maltol-induced gene mutations in bacteria (Bjeldanes and Chew, 1979) and sister chromatid
exchanges (SCEs) in human lymphocytes (Jansson et al., 1986). In vivo, maltol-induced
micronuclei in mouse bone marrow after intraperitoneal application (Hayashi et al., 1988).
Negative results were obtained in a sex-linked recessive lethal mutation assay in Drosophila
(Mason et al., 1992). However, the micronucleus assay is considered more relevant than the
Drosophila assay.
• Ethyl maltol-induced gene mutations in bacteria (Bjeldanes and Chew, 1979).
• A negative result was obtained with β-ionone in a gene mutation assay in bacteria 
(Mortelmans et al., 1986).
The validity of other studies was limited or could not be evaluated.
2.4.3. Carcinogenicity studies
In a combined study of developmental toxicity and carcinogenicity, three successive generations of
male and female Charles River CD-COBS rats received 3-ethyl-2-hydroxy-2-cyclopenten-1-one (owing
to keto–enol tautomerism this substance can exist as two isomers; the keto-isomer is 3-
ethylcyclopentan-1,2-dione [FL-no: 07.057], a synonym for the keto-isomer is ethylcyclopentenolone)
in the basal diet at doses of 0 (untreated control), 0 (propylene glycol control), 30, 80 or 200 mg/kg
body weight (bw) per day. The F1 generation was initially exposed in utero, subsequently via the
dams’ milk until weaning, and then treated for two years and bred twice (at days 99 and 155). In the
F1 generation, there were 100 animals of each sex in the untreated control group, 50 animals of each
sex in both the propylene glycol control and 3-ethyl-2-hydroxy-2-cyclopenten-1-one-treated groups.
Survival, clinical symptoms, food consumption, reproductive performance, haematological and clinical
chemistry parameters were not adversely affected. Gross pathological and histopathological
examination revealed no significant treatment-related effects. The incidence of benign or malignant
tumours in treated animals was similar to that in controls. The No Observed Effect Level (NOEL) was
200 mg/kg bw per day (King et al., 1979).
The Panel concluded that 3-ethyl-2-hydroxy-2-cyclopenten-1-one (3-ethylcyclopentan-1,2-dione [FL-
no: 07.057]) was not carcinogenic in rats under the study conditions.
Groups of 25 male and female rats were fed for two years on diets containing ethyl maltol [FL-no:
07.047] calculated to deliver 0, 50, 100 and 200 mg ethyl maltol/kg bw/day. No abnormalities were
5 The data presented in Section 2.4 are cited from the first version of the present FGE.213. These data are the basis for the
conclusions in FGE.213 requesting additional genotoxicity data.
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seen as regards survival, clinical appearance, growth rate or food consumption, clinical chemistry,
haematology and urinalysis. No histopathological changes and no increases in neoplasms were seen
after the treatment with ethyl maltol (Gralla et al., 1969).
Study validation and results are presented in Table 9.
The Panel noted that this study was performed before Organisation for Economic Co-operation and
Development (OECD) test guidelines 451/453 (1981a, b) had been established and it does not meet
the criteria of these OECD test guidelines with respect to the number of animals. However, the Panel
concluded that ethyl maltol was not carcinogenic in rats in this study.
2.4.4. Conclusion on genotoxicity and carcinogenicity
For the substances of this group, the applicability of the (Q)SAR models is very limited since many
substances were out of domain in the ISS model and the MultiCASE models.
Two substances [FL-nos: 02.106 and 09.305] are precursors of β-ionone [FL-no: 07.008] and 
therefore, the conclusions for these two precursors could be based on the conclusions drawn for the
corresponding ketone [FL-no: 07.008]. Maltyl isobutyrate [FL-no: 09.525] is a precursor of maltol [FL-
no: 07.014], and accordingly, the conclusion for maltyl isobutyrate could be based on the conclusion
drawn for maltol.
Maltol and ethyl maltol were considered separately because, in contrast to the other substances in this
subgroup, they contain a ring-oxygen atom.
A carcinogenicity study on ethyl maltol [FL-no: 07.047] in rats (Gralla et al., 1969) has been
evaluated. Although there were fewer animals per group than that suggested in OECD guidelines
451/453 (1981a, b), the study was in accordance with the standards available at that time. The Panel
concluded that the result from this study could overrule the mutagenicity observed with ethyl maltol in
bacteria, but not the mutagenicity observed with maltol [FL-no: 07.014] in vitro and in vivo. Since the
micronuclei induced by maltol in mice were analysed after intraperitoneal application, a micronucleus
assay after oral application is required, in addition to an in vivo comet assay, in order to clarify the
genotoxic potential of maltol. A combination of the micronucleus assay and the comet assay in a
single study would also be acceptable. The results of these assays would also be applicable to maltyl
isobutyrate [FL-no: 09.525], which is a precursor of maltol.
No carcinogenicity was observed with 3-ethyl-2-hydroxy-2-cyclopenten-1-one [FL-no: 07.057] in rats.
This substance was considered representative for nine substances [FL-nos: 07.117, 07.118, 07.119,
07.120, 07.056, 07.168, 07.075, 07.076 and 07.080]. Therefore, the Panel concluded that the
structural alert for genotoxicity is overruled for 3-ethyl-2-hydroxy-2-cyclopenten-1-one [FL-no:
07.057] as well as for the nine structurally related substances.
For the 13 remaining substances (including two precursors of a ketone) [FL-nos: 02.106, 07.008,
07.010, 07.041, 07.083, 07.089, 07.108, 07.109, 07.127, 07.136, 07.200, 09.305 and 16.044] a
genotoxic potential could not be ruled out since only one valid negative bacterial genotoxicity study on
[FL-no: 07.008] is available for these substances.
2.4.5. Conclusion based on the data available to the Panel in FGE.213
The Panel concluded that ethyl maltol [FL-no: 07.047], 3-ethylcyclopentan-1,2-dione [FL-no: 07.057]
and the nine structurally related substances [FL-nos: 07.117, 07.118, 07.119, 07.120, 07.056, 07.168,
07.075, 07.076 and 07.080] can be evaluated through the Procedure.
For maltol [FL-no: 07.014], a micronucleus assay after oral application is required, in addition to an in
vivo comet assay, in order to clarify the genotoxic potential. A combination of the micronucleus assay
and the comet assay in a single study would also be acceptable. The outcome would also be
applicable to maltyl isobutyrate [FL-no: 09.525].
At present, the remaining 13 substances (including two precursors of a ketone) [FL-nos: 02.106,
07.008, 07.010, 07.041, 07.083, 07.089, 07.108, 07.109, 07.127, 07.136, 07.200, 09.305 and 16.044]
cannot be evaluated using the Procedure. Additional data on genotoxicity are requested for the
representative substances of this subgroup according to the opinion of the Panel on the ‘Genotoxicity
Test Strategy for Substances Belonging to Subgroups of FGE.19’ (EFSA, 2008b).
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Additional genotoxicity data evaluated by the Panel in2.5.
FGE.213Rev16
2.5.1. Presentation of the additional data
Based on Panel requirements published in FGE.213 (EFSA, 2009), additional data have been provided
by the Flavour Industry for the representative substances: β-ionone [FL-no: 07.008], maltol [FL-no: 
07.014], β-damascone [FL-no: 07.083], nootkatone [FL-no: 07.089] and 2,6,6-trimethylcyclohex-2-en-
1,4-dione [FL-no: 07.109].
FGE.213, Revision 1 (FGE.213Rev1), includes the assessment of these additional genotoxicity studies
(Table 3).
Table 3: Studies evaluated in FGE.213Rev1
Substance/study type
Bacterial
Reverse
Mutation assay
In Vitro
Micronucleus test
In Vivo combined
Micronucleus test
and Comet assay
β-Ionone [FL-no: 07.008] Ballantyne, 2011 Stone, 2011a
Maltol [FL-no: 07.014] Ballantyne, 2012 Whitwell, 2012 Beevers, 2013a
β-Damascone [FL-no: 07.083] Bowen, 2011b Stone, 2012 Beevers, 2013b, c
Nootkatone [FL-no: 07.089] Marzin, 1998 Stone, 2011b
2,6,6-Trimethylcyclohex-2-en-1,4-
dione [FL-no: 07.109] Bowen, 2011a Lloyd, 2011
2.5.2. In vitro data
Bacterial reverse mutation assay
β-Ionone [FL-no: 07.008] 
β-Ionone [FL-no: 07.008] was tested in Salmonella typhimurium strains TA98, TA100, TA1535,
TA1537 and TA102 in the absence and presence of S9-mix (Ballantyne, 2011). In the first experiment,
the concentrations used were 0.32, 1.6, 8, 40, 200, 1 000 and 5 000 µg/plate of β-ionone and the 
plate incorporation methodology was used. Toxicity ranging from slight thinning of the background
lawn to complete killing of the tester strains was observed at 1 000 and/or 5 000 µg/plate for all
tester strains in the absence and presence of S9-mix. In the second experiment, the concentrations
tested were 10.24, 25.6, 64, 160, 400 and 1 000 µg/plate and the treatments in the presence of S9-
mix used the pre-incubation method. Toxicity ranging from thinning of the background lawn and/or
reduction in revertant numbers to complete killing of the tester bacteria occurred in all strains at
1 000 µg/plate in the absence and presence of S9-mix, and was also seen down to 160 and/or
400 µg/plate for some individual strains. The study design complied with current recommendations
and an acceptable highest concentration was achieved. There was clearly no evidence of any
mutagenic effect induced by β-ionone in any of the strains, either in the absence or presence of S9-
mix.
Maltol [FL-no: 07.014]
Maltol [FL-no: 07.014] was tested in S. typhimurium strains TA98, TA100, TA1535, TA1537 and
TA102 in the absence and presence of S9-mix (Ballantyne, 2012). In the first experiment, the
concentrations were 0.32, 1.6, 8, 40, 200, 1 000 and 5 000 µg/plate of maltol and the plate
incorporation methodology was used. Toxicity in the form of reduction of the number of revertants in
the tester strain TA102 was observed at concentrations of 200 µg/plate and greater in the presence of
6 The data presented in Section 2.5 are cited from FGE.213Rev1. These data are the basis for the conclusions in FGE.213Rev1
requesting additional data.
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S9-mix and 1 000 and 5000 µg/plate in the absence of S9-mix. In the second experiment, the
concentrations were 51.2, 128, 320, 800, 2 000 and 5 000 µg/plate and the treatments in the
presence of S9-mix used the pre-incubation method in all strains. In tester strain TA102 an additional
lower concentration of 20.48 µg/plate was incorporated into the testing protocol in both the absence
and presence of S9-mix to assess, more carefully, the toxicity observed in experiment 1. Toxicity in
the form of thinning of the background lawn and/or reduction in numbers of revertants occurred at
5 000 µg/plate in strain TA102 in the absence and presence of S9-mix, and in strain TA100 only in the
presence of S9-mix. The study design complied with current recommendations and an acceptable
highest concentration was achieved. There was no evidence of any mutagenic effect induced by
maltol in any of the strains, either in the absence or presence of S9-mix.
β-Damascone [FL-no: 07.083] 
An Ames assay was conducted in S. typhimurium strains TA98, TA100, TA1535, TA1537, and TA102
to assess the mutagenicity of β-damascone (purity: 95 %), both in the absence and in the presence of 
metabolic activation by S9-mix, in three separate experiments (Bowen, 2011b). The assay was
performed according to OECD Guideline 471 (1997a) and according to Good Laboratory Practice (GLP)
principles.
An initial experiment was carried out both in the absence and presence of S9-mix activation in all five
strains, using final concentrations of β-damascone between 0.32 and 5000 µg/plate (0.32, 1.6, 8, 40, 
200, 1 000, 5 000 µg/plate), plus negative (solvent) and positive controls. Evidence of toxicity was
observed through thinning of the background lawn to complete killing at concentrations of
1 000 µg/plate and greater for strains TA1535, TA1537 and TA102 and/or 5000 µg/plate for strains
TA98 and TA100 in the absence and presence of S9-mix. In the second experiment the highest
concentration was retained for strains TA98 and TA100 in the absence and presence of S9-mix. In all
other tester strains, the highest concentration was reduced to 2500 µg/plate based on toxicity
observations. In addition, more narrow concentration intervals were used, starting at either
78.13 µg/plate or 156.3 µg/plate (78.13, 156.3, 312.5, 625, 1250, 2500 µg/plate). The standard plate
incorporation assay was used in the first experiment but a pre-incubation step with S9-mix activation
treatment was added in the second experiment to increase the chance of detecting a positive
response. Evidence of toxicity was observed in TA98 at 625 µg/plate (in the presence of S9-mix) and
at concentrations of 1250 µg/plate and greater (in the absence of S9-mix). Evidence of toxicity was
observed in strains TA1535, TA1537 and TA102 at 625 µg/plate in the absence and presence of S9-
mix. In strain TA100 toxicity was observed at concentrations of 1250 µg/plate and greater (in the
presence of S9-mix) and at concentrations of 2500 µg/plate and greater (in the absence of S9-mix).
The third experiment was conducted using strain TA98 in the presence of S9-mix activation using the
pre-incubation method. The maximum test concentration was reduced to 1 250 µg/plate based on
toxicity observed in the previous experiments. In addition, more narrow concentration intervals were
used, covering 19.53 to 1 250 µg β-damascone/plate (19.53, 39.06, 78.13, 156.3, 312.5, 625 and 
1 250 µg/plate). Evidence of toxicity was observed at the highest four concentrations in strain TA98 in
the presence of S9-mix. In all three experiments, no statistically significant increases in revertant
numbers were observed at any concentration, in any of the strains, either in the presence or absence
of S9-mix activation.
The Panel agreed with the conclusion of the study authors that β-damascone did not induce mutations 
in five strains of S. typhimurium, when tested under the conditions of this study.
Nootkatone [FL-no: 07.089]
Nootkatone [FL-no: 07.089] was tested in S. typhimurium strains TA98, TA100, TA1535, TA1537 and
TA102 in the absence or presence of S9-mix (Marzin, 1998). A preliminary toxicity test to identify
appropriate concentrations for the mutagenicity assays was performed in the absence and presence of
S9-mix, and cytotoxicity was observed at 50 µg/plate in the absence of S9-mix and at 150 µg/plate in
the presence of S9-mix. In the first mutagenicity experiment using plate incorporation methodology
the concentrations tested were 0.5, 1.5, 5, 15 and 50 µg/plate in the absence of S9-mix metabolic
activation and 1.5, 5, 15, 50 and 150 µg/plate in the presence of S9-mix. In the second experiment
the plate incorporation method was used in the absence of S9-mix and the concentrations were 0.5,
1.5, 5, 15 and 50 µg/plate. While the pre-incubation method was used in the presence of S9-mix and
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the concentrations were 0.5, 1.5, 5, 15, 50 and 150 µg/plate. Thus, the study design complied with
current recommendations and an acceptable highest concentration was achieved. There was no
evidence of any mutagenic effect induced by nootkatone in any of the strains, either in the absence or
presence of S9-mix.
2,6,6-Trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109]
2,6,6-Trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109] was tested in S. typhimurium strains TA98,
TA100, TA1535, TA1537 and TA102 in the absence and presence of S9-mix (Bowen, 2011a). In the
first experiment, the concentrations tested were 0.32, 1.6, 8, 40, 200, 1 000 and 5 000 µg/plate and
plate incorporation methodology was used. In the second experiment, the concentrations were 156.3,
312.5, 625, 1 250, 2 500 and 5 000 µg/plate of 2,6,6-trimethylcyclohex-2-en-1,4-dione and
treatments in the presence of S9-mix used the pre-incubation method. The test chemical elicited
evidence of cytotoxicity in the form of background lawn thinning or marked reduction of the number
of revertants in experiment 1 at 1 000 and/or 5 000 µg/plate in strains TA102 and TA1535 in the
presence of S9-mix and in experiment 2 at 2 500 and/or 5 000 µg/plate in strain TA102 in the
absence and presence of S9-mix. Thus, the study design complied with current recommendations and
an acceptable highest concentration was achieved. There was no evidence of any mutagenic effect
induced by 2,6,6-trimethylcyclohex-2-en-1,4-dione in any of the strains, either in the absence or
presence of S9-mix.
Summary of the bacterial reverse mutation assay for all the substances is reported in Table 10.
Micronucleus Assay
β-Ionone [FL-no: 07.008] 
β-Ionone [FL-no: 07.008] was evaluated in an in vitro micronucleus assay in human peripheral blood
lymphocytes for its ability to induce chromosomal damage or aneuploidy in the presence and absence
of rat liver S9-mix fraction as an in vitro metabolising system. Cells were stimulated for 48 hours with
phytohaemagglutinin (PHA) to produce exponentially growing cells and then treated for 3 hours
(followed by a 21-hour recovery period) with 0, 30, 50 or 60 µg/ml of β-ionone in the absence of S9-
mix and 0, 80, 100 or 120 µg/ml in the presence of S9-mix. The levels of cytotoxicity (reduction in
replication index) at the highest concentrations were 52 % and 59 %, respectively.
In a parallel assay, cells were treated for 24 hours with 0, 5, 15 and 17.50 µg/ml of β-ionone in the 
absence of S9-mix with no recovery period. The highest concentration induced 58 % cytotoxicity.
There were 2 replicate cultures per treatment and 1000 binucleate cells per replicate were scored for
micronuclei. Thus, the study design complies with current recommendations (OECD Guideline 487),
and acceptable levels of cytotoxicity were achieved at the highest concentrations used in all parts of
the study. Treatment of cells with β-ionone for 3 hours with a 21-hour recovery period showed an 
increase in the frequency of micronucleated binucleated (MNBN) cells in one single replicate at
concentrations of 30 and 120 µg/ml (0.9 % and 1.5 %, respectively) in the absence and presence of
S9-mix, respectively. At 30 µg/ml, the lowest concentration tested in the absence of S9-mix, the
increase in the frequency of MNBN cells was slightly above the 95 % confidence interval of the
historical control range (0.2–0.8 %). In addition, in the presence of S9-mix, one replicate of the
lowest concentration tested (80 µg/ml) had an increase in the frequency of MNBN cells at the upper
limit of the 95 % confidence interval of the historical control range (0.10–1.10 %) but did not reach
statistical significance. To ensure that these single occurrences are random an additional 1 000
binucleate cells were scored from the concurrent controls, 80 and 120 µg/ml cultures. The scoring of
further cells resulted in overall mean frequencies of MNBN cells that were not significantly different
from concurrent controls and fell below the upper 95 % confidence interval of the normal control
range (recalculated due to change of stain), and therefore showed that the earlier increases were due
to chance. It was concluded that β-ionone [FL-no: 07.008] did not induce micronuclei up to toxic 
concentrations when assayed in cultured human peripheral lymphocytes for 3 + 21 hours in the
absence and presence of S9-mix or when incubated for 24 + 0 hours in the absence of S9-mix (Stone,
2011a).
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Maltol [FL-no: 07.014]
Maltol [FL-no: 07.014] was evaluated in an in vitro micronucleus assay in human peripheral blood
lymphocytes for its ability to induce chromosomal damage or aneuploidy in the presence and absence
of rat liver S9-mix fraction as an in vitro metabolising system (Whitwell, 2012). Cells were stimulated
for 48 hours with PHA to produce exponentially growing cells and then treated for 3 hours (followed
by a 21-hour recovery period) with 0, 400, 800 or 1 262 µg/ml of maltol, the last being equivalent to
10 mM, in the absence and presence of S9-mix. The levels of cytotoxicity (reduction in replication
index) at the highest concentrations were 24 % and 19 %, respectively. In a parallel assay, cells were
treated for 24 hours with 0, 125, 200 and 300 µg/ml of maltol in the absence of S9-mix with no
recovery period. The highest concentration induced 57 % cytotoxicity. There were 2 replicate cultures
per treatment, and 1 000 binucleate cells per replicate (i.e. 2 000 cells per concentration) were scored
for micronuclei. Thus, the study design complies with current recommendations (OECD Guideline
487), and acceptable highest concentrations, either 10 mM or 50–60 % toxicity, were achieved in all
parts of the study. A statistically significant increase in the occurrence of MNBN cells was observed
following 3 + 21 hours treatment in the presence of S9-mix at the two highest concentrations scored.
Statistically significant and concentration-dependent increases in MNBN cells were seen in the 3 + 21
hours treatment groups in the absence of S9-mix, but it was noted that the increases at the two
highest concentrations scored exceeded historical control ranges in only one of the two replicate
cultures. No increases were observed in the frequency of MNBN cells in those that had received
continuous (24 + 0 hours) treatment, but due to the cytotoxicity of maltol, lower concentrations were
analysed. To further investigate these observations, fluorescence in situ hybridisation (FISH) analysis
using human pan-centromeric probes was conducted to assess whether the mechanism of action
could be attributed to chromosome loss (aneuploidy) or chromosome breakage (clastogenicity). Slides
were prepared from the two highest concentrations (800 and 1 262 µg/ml) in the absence and
presence of S9-mix. The FISH analysis revealed that following maltol treatment the majority (69–
76 %) of micronuclei did not contain a centromere. The Panel concluded that maltol induced
micronuclei in vitro in cultured human peripheral blood lymphocytes in the presence of rat liver
metabolic activation (S9-mix) via a clastogenic mechanism of action (Whitwell, 2012). However, the
Panel considered that the results observed in the absence of S9-mix were equivocal because of the
fact that the increases observed (which were statistically significantly different from concurrent
solvent control) were not reproduced in replicate cultures.
β-Damascone [FL-no:07.083] 
β-Damascone (purity: 95 %) was evaluated in an in vitro micronucleus assay in human peripheral
blood lymphocytes for its ability to induce chromosomal damage or aneuploidy in the presence or
absence of rat S9 fraction as an in vitro metabolising system (Stone, 2012). Cells were stimulated for
48 hours with PHA to produce exponentially growing cells and then treated for 3 hours (followed by a
21-hour recovery period) with concentrations ranging from 2 to 30 µg/ml. For the treatment of 3
hours with a 21-hour recovery period, the concentrations of β-damascone at 8, 16 and 22 µg/ml or at 
12, 16, 18 µg/ml were retained for micronuclei (MN) numeration, in the absence or in the presence of
S9-mix respectively. The levels of cytotoxicity (reduction in replication index) at the top concentrations
were 59 % and 51 %, respectively. Thus, the study design complies with OECD Guideline 487 and
follows GLP principles.
In a parallel assay, cells were treated for 24 hours (with no recovery period) in the absence of S9-mix
with concentrations ranging from 1 to 15 µg/ml, and the concentrations of 6, 8 and 9 µg/ml of β-
damascone were retained for MN numeration. The highest concentration induced 57 % cytotoxicity.
There were 2 replicate cultures per treatment and 1 000 binucleate cells per replicate were scored for
micronuclei. The study design complies with current recommendations (OECD Guideline 487, 2010),
and acceptable levels of cytotoxicity were achieved at the highest concentrations used in all parts of
the study.
Treatment of cells with β-damascone for 3 + 21 hours in the presence of S9-mix showed a statistically 
significant concentration-dependent increase in the induction of MNBN cells with 0.55, 2.10 and
2.70 % MNBN cells versus 0.35 % in the concurrent control and 0.1 to 1.1 % for the historical
controls.
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Treatment of cells with β-damascone for 3 + 21 and 24 + 0 hours in the absence of S9-mix resulted 
in sporadic increases in MNBN frequency. These increases were only observed in single replicates and
were not concentration-related. Therefore, the effect of β-damascone was further investigated 
through the scoring of additional cells (2 more replicates of 1000 cells each) from the affected
concentrations and concurrent controls.
Treatment of cells, in the absence of S9-mix, for 3 + 21 hours induced a statistically significant
increase in the frequency of MNBN cells at 8 and 22 µg/ml (0.80 % and 0.93 %, respectively)
compared with concurrent control (0.38 %), but not at the mid-dose of 16 µg/ml (0.53 % MNBN
cells). The frequency of MNBN cells exceeded the historical controls (0.2–0.8 %) in 3 out of 4
replicates at the highest concentration tested (22 µg/ml). Treatment of cells for 24 hours with no
recovery period in the absence of S9-mix showed a statistically significant increase in the frequency of
MNBN cells at the mid-dose of 8 µg/ml (0.95 % MNBN cells) when compared with concurrent control
(0.40 %) with no correlation to concentration. The frequency of MNBN cells exceeded the historical
controls (0–1.1 %) in only one replicate at 8 µg/ml.
The authors considered that this result reaffirmed the sporadic nature of the induction of MNBN cells
in the absence of S9-mix. It was concluded that the treatment with β-damascone for 3 + 21 hours or 
24 + 0 hours (in the absence of S9-mix) induced sporadic increases in MNBN cells when compared
with concurrent controls and not concentration-related; therefore, the results were considered
equivocal. In the same test system, β-damascone induced micronuclei in cultured human peripheral 
blood lymphocytes following 3 + 21 hours treatment in the presence of S9-mix (Stone, 2012). The
Panel noted that after the new reading of slides the increase in the frequency of MNBN cells was still
statistically significant even at weak cytotoxic levels.
Therefore, the Panel concluded that β-damascone is genotoxic in the in vitro micronucleus assay on
human lymphocytes with metabolic activation and equivocal without metabolic activation.
Nootkatone [FL-no: 07.089]
Nootkatone [FL-no: 07.089] was evaluated in an in vitro micronucleus assay in human peripheral
blood lymphocytes for its ability to induce chromosomal damage or aneuploidy in the presence and
absence of rat S9-mix fraction as an in vitro metabolising system (Stone, 2011b). Cells were
stimulated for 48 hours with PHA to produce exponentially growing cells and then treated for 3 hours
(followed by a 21-hour recovery period) with 0, 50, 70 or 80 µg/ml of nootkatone in the absence of
S9-mix and 0, 160, 180 and 185 µg/ml in the presence of S9-mix, respectively. The levels of
cytotoxicity (reduction in replication index) at the highest concentrations were 60 % and 58 %,
respectively. In a parallel assay, cells were treated for 24 hours with 0, 10, 15, 22 and 24 µg/ml of
nootkatone in the absence of S9-mix with no recovery period. The highest concentration induced
62 % cytotoxicity. There were 2 replicate cultures per treatment and 1 000 binucleate cells per
replicate (i.e. 2 000 cells per dose) were scored for micronuclei. The study design complies with
current recommendations (OECD Guideline 487) and acceptable levels of cytotoxicity were achieved at
the highest concentrations used in all parts of the study. No evidence of chromosomal damage or
aneuploidy was observed as frequencies of MNBN cells were not significantly different from concurrent
controls and fell within historical control ranges for all treatments with nootkatone in the presence or
absence of S9-mix metabolic activation (Stone, 2011b).
2,6,6-Trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109]
2,6,6-Trimethylcyclohex-2-en-1,4-dione was evaluated in an in vitro micronucleus assay in human
peripheral blood lymphocytes for its ability to induce chromosomal damage or aneuploidy in the
presence and absence of rat S9-mix fraction as an in vitro metabolising system (Lloyd, 2011). Cells
were stimulated for 48 hours with PHA to produce exponentially growing cells and then treated for 3
hours (followed by a 21-hour recovery period) with 0, 500, 1 000 or 1 522 µg/ml of 2,6,6-
trimethylcyclohex-2-ene-1,4-dione in the absence of S9-mix and 0, 1 000, 1 250 and 1 522 µg/ml in
the presence of S9-mix, the highest concentration being equivalent to 10 mM. The levels of
cytotoxicity (reduction in replication index) at the highest concentrations were 3 % and 9 %,
respectively. In a parallel assay, cells were treated for 24 hours with 0, 300, 420 and 550 µg/ml of
2,6,6-trimethylcyclohex-2-ene-1,4-dione in the absence of S9-mix with no recovery period. The
highest concentration induced 57 % cytotoxicity. There were 2 replicate cultures per treatment and
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1 000 binucleate cells per replicate (i.e. 2 000 cells per concentration) were scored for micronuclei.
The study design complies with current recommendations (OECD Guideline 487), and acceptable
highest concentrations, either 10 mM or 50–60 % toxicity, were achieved in all parts of the study. No
evidence of chromosomal damage or aneuploidy was observed as frequencies of MNBN cells were not
significantly different from concurrent controls and fell within historical ranges for all 2,6,6-
trimethylcyclohex-2-ene-1,4-dione treatments in the presence or absence of S9-mix metabolic
activation (Lloyd, 2011).
The results of in vitro micronucleus studies are summarised in Table 10.
2.5.3. Genotoxicity in vivo data
In vivo Combination Assay (comet + micronucleus tests)
Since no positive results were seen in either the bacterial mutation assay or in vitro micronucleus tests
with β-ionone [FL-no: 07.008], nootkatone [FL-no: 07.089] or 2,6,6-trimethylcyclohex-2-en-1,4-dione 
[FL-no: 07.109], no in vivo follow-up testing was required. To address the effects seen in the in vitro
micronucleus assay with maltol [FL-no: 07.014] and β-damascone [FL-no: 07.083] a combination 
assay comprising a liver comet assay and an in vivo micronucleus assay in rats, after oral application,
was performed to further assess the genotoxic potential for both substances. The results are
summarised in Table 11.
Maltol [FL-no: 07.014]
Maltol was evaluated in an in vivo bone marrow micronucleus assay and liver comet assay in male
Han Wistar (HsdHan:WIST) rats, with 6 rats per dose group (Beevers, 2013a). The rats were
administered 3 doses of 70, 350 and 700 mg/kg bw of maltol by oral gavage at time 0, 24 and 45
hours. Rats were killed and sampled at 48 hours post the initial dose. The maximum tolerable dose
was estimated to be 700 mg/kg bw/day based on a range-finding study where maltol was tested at
360, 500, 700, 1 000, 1 500 and 2 000 mg/kg bw/day. Clinical observations (piloerection, ataxia,
bradypnoea) and mortalities were observed at doses of 1000 mg/kg bw/day and greater. For the
micronucleus assay 2 000 polychromatic erythrocytes (PCE) per rat were scored. The negative control
had a normal, low frequency (0.11 %) of micronucleated polychromatic erythrocytes (MNPCEs) and a
ratio of 53.7 % PCE. The positive control group resulted in a significant increase in MNPCEs (1.58 %)
accompanied by some bone marrow toxicity (29.57 % PCE). Although an individual rat in the
700 mg/kg maltol dose group showed a frequency of 9 MNPCEs, which resulted in significant
heterogeneity in this dose group, this was considered an outlying data point because the other 5 rats
in the group were exhibiting normal control-level MNPCE frequencies (Beevers, 2013a). Overall, the
results showed that there were no statistically significant increases in micronucleus frequency for any
dose group after oral treatment with maltol when compared with the vehicle control group. However,
in the main experiment, at the dose levels selected, no clinical signs and bone marrow toxicity were
observed in any animal in the maltol-treated groups, which may reflect the possibility that the bone
marrow and liver were not exposed.
In order to clarify this issue, the Panel requested plasma analysis for proof of exposure. Plasma was
obtained from two satellite groups of male animals (3 + 3 animals) dosed with maltol by oral gavage
at 700 mg/kg bw/day, during conduction of the main study (Beevers, 2013a). Plasma obtained from
0.5 ml blood drawn from the jugular vein from each animal was frozen in the event that analysis for
proof of exposure and toxicokinetics were required. All doses of maltol were given as three
administrations, at 0, 24 and 45 hours. Three samples of plasma were obtained from one group of
animals at 0.5, 2 and 8 hours and three samples from the other group at 1, 4 and 24 hours from the
last administration. Analysis of maltol in plasma was performed using a gas chromatography with
mass selective detection (GC-MSD) method. From an analytical point of view, the Panel considered the
employed approach, which was based on the use of ethylmaltol as an internal standard, as sufficient.
Results showed a marked inconsistency between sampling times and animals. In samples collected at
0.5, 2 and 8 hours from last administration maltol was found in 2 out of 3 satellite animals at plasma
concentrations of 265–283 µg/ml after 0.5 and 2 hours, but no longer detectable after 8 hours. In the
plasma of the third animal maltol was not detectable at any time. On the other hand, in samples from
another animal group (n = 3) collected at 1, 4 and 24 hours from last administration, maltol was
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found at levels of 75–106 µg/l after 1 hour in all 3 animals and no longer detectable after 4 and 24
hours (Mallinson and Hough, 2014). The authors concluded that the results obtained provided
evidence that maltol is present in plasma shortly after dosing. However, the Panel did not agree with
this conclusion and it considered the results of the bioanalytical study as inconclusive.
In the combined comet assay, livers of rats were removed at 48 hours after the first dose (i.e. 3 hours
after the final dose), cut into small pieces and forced through a bolting cloth. Single cell suspensions
were embedded in low melting point agarose on slides and lysed. The DNA was unwound and
subjected to electrophoresis at pH > 13 and then neutralised according to standard techniques. For
each animal, 100 cells (50 cells/slide from 2 slides) were scored for comets (tail intensity and tail
moment) using commercial image analysis equipment.
The comet assay did not reveal cytotoxicity, necrosis or apoptosis in the hepatocytes as assessed by
cloud and halo analysis and the groups treated with maltol showed mean percentage tail intensities
and tail moments that were similar to vehicle controls and fell within historical control ranges. The
positive control group treated with ethyl methanesulphonate showed significant increases in both
parameters (Beevers, 2013a).
Considering that maltol has been shown to induce micronuclei in mouse bone marrow after
intraperitoneal injection (Hayashi et al., 1988), the Panel concludes that negative findings observed in
the combined bone marrow micronucleus test and comet assay in the liver of treated rats could not
rule out the concern for genotoxicity for maltol since the data provided to prove systemic availability
were considered inconclusive due to the inconsistency of the data.
β-Damascone [FL-no:07.083] 
A combined in vivo micronucleus assay and comet assay was performed after oral application of β-
damascone (purity: 95.6 %) to further assess the genotoxic potential of β-damascone and 
damascones more generally. The results are summarised in Table 11. β-Damascone was evaluated in 
an in vivo bone marrow micronucleus assay and liver and duodenum comet assay in groups of 6 male
Han Wistar (HsdHan:WIST) rats per dose group (Beevers, 2013c). Based on a range-finding study,
500 mg/kg/day was considered an appropriate estimate of the maximum tolerated dose (MTD)
because doses of 750 mg/kg/day and greater induced moderate to severe clinical signs of toxicity,
which included piloerection, decreased activity, hunched posture and abnormal breathing. The rats
were administered 3 doses of 125, 250 and 500 mg/kg bw of β-damascone by oral gavage at time 0, 
24 and 45 hours. The rats were sacrificed and sampled at 48 hours post the initial dose.
Animals administered β-damascone showed clear findings during pathological analysis. Hepatocyte 
vacuolation was present in animals given 500 mg/kg/day, and was characterised by scattered,
occasionally shrunken hepatocytes with perinuclear cytoplasmic eosinophilia and peripheral
cytoplasmic vacuolation. Single cell necrosis was present in a single animal given 500 mg/kg/day.
Single cell necrosis was characterised by death of individual hepatocytes throughout the liver, with
limited inflammatory cell involvement. There was a dose-related reduction in the level of glycogen
vacuolation in animals given 250 or 500 mg/kg/day. Glycogen vacuolation was characterised by
generally perinuclear, clear, variably sized, indistinctly defined, vacuoles. Finally, increased mitosis was
present in animals from all groups given β-damascone. The greatest severity was present in animals 
given 250 mg/kg/day, and the lowest incidence was present in animals given 500 mg/kg/day.
Increased mitosis was characterised by an increase, above the normal low background incidence, of
mitotic figures within the liver parenchyma. Collectively, these findings indicate that the test animals
were systemically exposed to β-damascone. 
The negative control had a 0.11 % average rate of MNPCE and a ratio of 50.2 % PCE; the 125 mg/kg
β-damascone treatment group had a MNPCE rate of 0.09 % and PCE ratio of 49.17 %; the 250 mg/kg 
treatment group had a 0.09 % MNPCE rate and 52.30 % PCE ratio; the 500 mg/kg treatment group
showed 0.06 % MNPCEs and 37.63 % PCE ratio. The positive control group resulted in 1.54 %
MNPCEs and a 43.17 % PCE ratio (Beevers, 2013c). The group mean frequencies observed were
similar to concurrent vehicle controls for all dose groups and also were within the historical control
values (mean: 0.12 %). There was a reduction in PCE ratio at the highest dose level indicating bone
marrow toxicity, which demonstrates target organ exposure. These results showed that there was no
statistically significant increase in micronuclei induced with β-damascone under these test conditions 
when compared with the negative control group. In addition, there were no statistically significant
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differences among erythrocyte parameters examined in this study. It was concluded that β-
damascone did not induce micronucleated erythrocytes in rat bone marrow cells following
administration by oral gavage.
The comet assay in the liver tissue did not reveal cytotoxicity, necrosis or apoptosis in the hepatocytes
as assessed by cloud and halo analysis. Hepatocytes of rats dosed with β-damascone were evaluated 
for percentage tail intensities and tail moments (± standard error of the mean, SEM); the 125 mg/kg
β-damascone group had 2.45 ± 0.13 % tail intensity and 0.27 ± 0.02 % tail moment; the 250 mg/kg 
group had 2.99 ± 0.31 % tail intensity and 0.33 ± 0.03 tail moment; the 500 mg/kg group had
2.93 ± 0.24 % tail intensity and 0.31 ± 0.03 tail moment, which were similar to concurrent vehicle
controls (tail intensity of 2.67 ± 0.26 % and 0.29 ± 0.03 tail moment) and fell within the testing
laboratories historical control range for vehicle controls (0.3–8.15 % tail intensity and 0.04–0.81 tail
moment). The comet arm of this study confirms that β-damascone did not induce DNA damage in the 
liver under the conditions of this study (Beevers, 2013c).
In a satellite study the slides from the duodenum tissue samples collected in the above study
(Beevers, 2013c) were analysed for comet tailing effects (Beevers, 2013b). Duodenum cells of rats
dosed with β-damascone were evaluated for percentage tail intensities and tail moments (± standard 
error of the mean, SEM); the 125 mg/kg β-damascone group had 2.01 ± 0.43 % tail intensity and 
0.32 ± 0.03 % tail moment; the 250 mg/kg group had 1.47 ± 0.15 % tail intensity and 0.16 ± 0.02
tail moment; the 500 mg/kg group had 2.03 ± 0.19 % tail intensity and 0.19 ± 0.02 tail moment,
which were similar to concurrent vehicle controls (tail intensity of 2.24 ± 0.43 % and 0.23 ± 0.04 %
tail moment) and fell within the testing laboratories historical control range for vehicle controls (0.3–
8.15 % tail intensity and 0.04–0.81 tail moment). The duodenum comet arm of this study confirms
that β-damascone did not induce DNA damage in the duodenum under the conditions of this study. 
The vehicle control data were within historical control ranges (95 % reference range: 0.77 to 8.32 %
for tail intensity and 0.08 to 1.15 % for tail moment) and the positive control induced a clear increase
in DNA damage. The study was therefore confirmed as valid. There was no evidence of duodenum
toxicity as would be suggested by increases in clouds or halo cells.
The percentage tail intensity and tail moment at all dose levels were very similar to the concurrent
vehicle control, thus confirming there is no test article-related DNA damage. The additional tissue
sample analysis for comet tailing showed a negative result for this study (Beevers, 2013b).
The results from the combined in vivo micronucleus induction study and comet assay show that orally
administered β-damascone did not induce micronucleated erythrocytes in rat bone marrow cells nor 
genotoxic events in liver and duodenum of rats.
2.5.4. Conclusion
Flavouring Group Evaluation 213 concerned 26 substances, corresponding to subgroup 2.7 of FGE.19
(see Table 4). Twenty-three of the substances are α,β-unsaturated alicyclic ketones [FL-nos: 07.008, 
07.010, 07.014, 07.041, 07.047, 07.056, 07.057, 07.075, 07.076, 07.080, 07.083, 07.089, 07.108,
07.109, 07.117, 07.118, 07.119, 07.120, 07.127, 07.136, 07.168, 07.200 and 07.224] and three are
precursors for such ketones [FL-nos: 02.106, 09.305 and 09.525].
For 11 substances [FL-nos: 07.047, 07.056, 07.057, 07.075, 07.076, 07.080, 07.117, 07.118, 07.119,
07.120 and 07.168] the Panel have ruled out concerns regarding genotoxicity in FGE.213.
In FGE.213Rev1, new data have been evaluated for the representative of the remaining substances.
More specifically, data for β-ionone [FL-no: 07.008], β-damascone [FL-no: 07.083], maltol [FL-no: 
07.014], nootkatone [FL-no: 07.089] and 2,6,6-trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109]. All
these studies are fully compliant with current guidelines, and stand in contrast to earlier studies
previously evaluated in FGE.213.
The combined evidence from in vitro and in vivo genotoxicity data for the selected representative
substances β-ionone [FL-no: 07.008], β-damascone [FL-no: 07.083], nootkatone [FL-no: 07.089] and 
2,6,6-trimethylcyclohex-2-en-1,4-dione [FL-no: 07.109] does not indicate a genotoxic potential.
Therefore, these substances and the nine substances that they represent [FL-nos: 02.106, 07.010,
07.041, 07.108, 07.127, 07.136, 07.200, 07.224 and 09.305] could be evaluated through the
Procedure.
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For maltol [FL-no: 07.014] and maltyl isobutyrate [FL-no: 09.525], the Panel concluded that the
concern for genotoxicity could not be ruled out.
3. Assessment
Additional data evaluated by the Panel in FGE.213Rev23.1.
3.1.1. Plasma bioanalysis
Since data provided to prove the systemic exposure to maltol of the animals tested in the combined
bone marrow micronucleus test and comet assay in liver (Beevers, 2013a) were considered
inconclusive in FGE.213Rev1, the Flavour Industry has submitted a new plasma bioanalysis (Beevers,
2015).
Six male Han Wistar rats were dosed at 700 mg maltol/kg bw/day (determined previously as an
estimate of the MTD), using the same dosing regimen employed in the combined micronucleus test
and comet assay (Beevers, 2013a).
Maltol was prepared as a suspension 0.5 % (w/v) in aqueous methylcellulose and administered via
oral gavage at: 0 (day 1), 24 (day 2) and 45 (day 3) hours. Whole blood was collected at 0.5, 1, 2
and 3 hours after dosing on day 3. Plasma was isolated and analysed using GC–MSD. Ethyl maltol was
used as an internal standard.
Detectable levels of maltol were found in all plasma samples isolated at 0.5, 1 and 2 hours after
dosing. Peak plasma levels of maltol were seen in the majority of animals at 0.5 hours after dose
administration. The concentration of maltol detected in plasma was different between the animals of 2
separate cages (treated with the same dose) and the authors of the study did not identify any
technical reasons that could account for this difference. However, it was concluded that data
demonstrate the presence of maltol in blood and that accordingly the bone marrow could be
considered exposed.
3.1.2. Additional in vitro data on maltol
An in vitro chromosomal aberration assay on maltol (not available before) is considered in the present
revision of FGE.213. Maltol (purity 99 %) was tested in CHL fibroblast cell line at three concentrations:
25, 50 and 75 µg/ml. Cells were harvested for chromosomal preparations after 24 hours or 48 hours
from the beginning of the treatment; metabolic activation was not included. Structural chromosomal
aberrations were observed at the 2 highest concentrations tested after both 24 hours and 48 hours of
treatment. These increases were concentration related, polyploidy was not observed (Ishidate, 1988).
The result obtained in this study is consistent with the clastogenic effect of maltol observed in the
study by Whitwell (2012), described in Section 2.5.2.
3.1.3. Additional information on p-mentha-1,4(8)-dien-3-one [FL-no:
07.127]
In FGE.213Rev1, the Panel concluded that the genotoxicity concern for p-mentha-1,4(8)-dien-3-one
[FL-no: 07.127] could be ruled out based on available genotoxicity data on structurally related
substances and consequently could be evaluated through the Procedure in FGE.57Rev1.
During the evaluation of p-mentha-1,4(8)-dien-3-one [FL-no: 07.127] through the Procedure, the
Panel noted that the chemical structure of p-mentha-1,4(8)-dien-3-one [FL-no: 07.127] is actually
more closely related to the structure of pulegone than to the structures used for the read-across
approach in FGE.213Rev1.
New information was found on genotoxicity and carcinogenicity of pulegone, based on which
additional data are expected to be provided by the applicant. At present, the data available on
pulegone and on the structurally related substance p-mentha-1,4(8)-dien-3-one [FL-no: 07.127] do
not rule out the concern for genotoxicity and carcinogenicity. Therefore p-mentha-1,4(8)-dien-3-one
[FL-no: 07.127] will be re-evaluated pending the submission of additional genotoxicity data.
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4. Conclusion
The Panel considered the available genotoxicity studies on maltol. An in vivo study in mice (by
intraperitoneal route) showed that maltol induced a statistically significant increase in the incidence of
micronuclei in bone marrow cells. Since maltol is intended to be used as food flavouring agent, the in
vivo study performed by gavage (combined micronucleus test and comet assay in rats) was
considered more relevant, but in the previous revision of that opinion, this study did not allow
conclusions on the genotoxicity of maltol to be made because exposure of target tissue was not
demonstrated. Therefore, the Panel requested to investigate the systemic exposure of animals to
maltol.
The Panel considered the new plasma bioanalysis for maltol and concluded that, based on the new
data provided, it now seems justifiable to assume that the animals were systemically exposed to
maltol and that the bone marrow was exposed in the in vivo micronucleus assay.
Therefore, the negative result of the in vivo micronucleus assay can be considered reliable and,
accordingly, the concern for genotoxicity for maltol [FL-no: 07.014] and for maltyl isobutyrate [FL-no:
09.525] in food is ruled out; both substances were evaluated by JECFA before 2000 and no EFSA
consideration is required.
The Panel reconsidered the available data on p-mentha-1,4(8)-dien-3-one [FL-no: 07.127] based on
new data for the structurally related substance pulegone, and concluded that additional genotoxicity
data are needed for [FL-no: 07.127] to rule out the concern for genotoxicity.
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Summary of Specification for Substances in FGE.213 (JECFA 1998, 2000, 2005a, b, 2009b)4.1.
Table 4: Specification summary of the substances in FGE.213
FL-no
JECFA-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility (a)
Solubility in
ethanol (b)
Boiling point, °C(c)
Melting point, °C
ID test
Assay minimum
Refrac. Index (d)
Spec.gravity (e)
02.106
392
4-(2,2,6-Trimethyl-1-
cyclohexenyl)but-3-en-2-ol
3625
–
22029-76-1
Liquid
C13H22O
194.32
–
–
107 (4 hPa)
–
IR
92 %
1.499
0.927–0.933
07.008
389
β-Ionone 2595
142
14901-07-6
Liquid
C13H20O
192.30
Insoluble
1 ml in 3 ml
70 % alcohol
239
–
IR
95 %
1.517–1.522
0.940–0.947
07.010
399
Methyl-β-ionone 2712
144
127-43-5
Liquid
C14H22O
206.33
–
–
238–242
–
IR
88 %
1.503–1.508
0.930–0.935
07.014
1480
Maltol 2656
148
118-71-8
Solid
C6H6O3
126.11
Very slightly
soluble
Soluble
–
159–162
NMR
98 %
n.a.
n.a.
07.041 β-Isomethylionone 4151
650
79-89-0
Solid
C14H22O
206.32
–
Freely soluble
334
62
–
95 %
n.a.
n.a.
07.047
1481
Ethyl maltol 3487
692
4940-11-8
Solid
C7H8O3
140.14
Soluble
Soluble
–
89–93
NMR
99 %
n.a.
n.a.
OH
O
O
O
O
OH
O
O
O
OH
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FL-no
JECFA-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility (a)
Solubility in
ethanol (b)
Boiling point, °C(c)
Melting point, °C
ID test
Assay minimum
Refrac. Index (d)
Spec.gravity (e)
07.056
418
3-Methylcyclopentan-1,2-dione 2700
758
80-71-7
Solid
C6H8O2
112.13
1 g in 72 ml
water
1 g in 5 ml 90 %
alcohol
–
104–108
IR
95 %
–
–
07.057
419
3-Ethylcyclopentan-1,2-dione 3152
759
21835-01-8
Solid
C7H10O2
126.16
Miscible
–
78–80 (5 hPa)
36–43
IR
90 %
1.47–1.48 (25°)
1.060–1.066
07.075
420
3,4-Dimethylcyclopentan-1,2-
dione
3268
2234
13494-06-9
Solid
C7H10O2
126.16
–
–
66 (1 hPa)
68–72
IR
98 %
–
–
07.076
421
3,5-Dimethylcyclopentan-1,2-
dione
3269
2235
13494-07-0
Solid
C7H10O2
126.16
Insoluble
–
–
87–93
MS
98 %
–
–
07.080
425
3-Methylcyclohexan-1,2-dione 3305
2311
3008-43-3
Solid
C7H10O2
126.16
Insoluble
–
69–72 (1 hPa)
57–63
IR
98 %
–
–
07.083
384
β-Damascone 
O 3243
2340
23726-92-3
Liquid
C13H20O
192.30
–
1 ml in 10 ml
95 %
67–70
–
IR
90 %
1.496–1.501
0.934–0.942 (20°)
07.089
1398
Nootkatone 3166
11164
4674-50-4
Liquid
C15H22O
218.35
Slightly soluble
Soluble
73–103 (1 hPa)
–
NMR
93 %
1.510–1.523
1.003–1.032
07.108
387
β-Damascenone 3420
11197
23696-85-7
Liquid
C13H18O
190.28
–
1 ml in 10 ml
95 % alcohol
60
–
IR
98 %
1.508–1.514
0.945–0.952 (20°)
O
O
OH
O
O
O
OH
O
O
O
OH
O
O
O
OH
O
O
O
O
OH
O
O
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FL-no
JECFA-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility (a)
Solubility in
ethanol (b)
Boiling point, °C(c)
Melting point, °C
ID test
Assay minimum
Refrac. Index (d)
Spec.gravity (e)
07.109
1857
2,6,6-Trimethylcyclohex-2-en-
1,4-dione
3421
11200
1125-21-9
Solid
C9H12O2
152.2
Slightly soluble
Soluble
222
23–28
IR NMR
98 %
n.a.
n.a.
07.117
422
3-Ethyl-2-hydroxy-4-
methylcyclopent-2-en-1-one
3453
11077
42348-12-9
Liquid
C8H12O2
140.18
Slightly insoluble
Miscible
–
–
NMR
99 %
1.481–1.487
1.055–1.061
07.118
423
5-Ethyl-2-hydroxy-3-
methylcyclopent-2-en-1-one
3454
11078
53263-58-4
Liquid
C8H12O2
140.18
Slightly soluble
Soluble
–
–
NMR
99 %
1.478–1.484
1.053–1.060
07.119
424
2-Hydroxycyclohex-2-en-1-one 3458
11046
10316-66-2
Solid
C6H8O2
112.13
Soluble
Soluble
53 (3 hPa)
35–38
IR
99.3 %
–
–
07.120
426
2-Hydroxy-3,5,5-
trimethylcyclohex-2-en-1-one
3459
11198
4883-60-7
Solid
C9H14O2
154.21
Slightly soluble
Soluble
90–100 (20 hPa)
88
IR
99 %
–
–
07.127
757
p-Mentha-1,4(8)-dien-3-one 3560
11189
491-09-8
Liquid
C10H14O
150.22
Insoluble
Miscible
233
–
MS
95 %
1.472–1.478
0.976–0.983
07.136
1405
4,4a,5,6-Tetrahydro-7-
methylnapthalen-2(3H)-one
3715
–
34545-88-5
Solid
C11H14O
162.23
Insoluble
Soluble
n.a.
36–37
IR
99 %
n.a.
n.a.
07.168
2038
2-Hydroxypiperitone 4143
–
490-03-9
Solid
C10H16O2
168.24
Slightly soluble
Freely soluble
233
82
NMR MS
98 %
n.a.
n.a.
07.200 4-(2,5,6,6-Tetramethyl-1-
cyclohexenyl)but-3-en-2-one
–
–
79-70-9
Liquid
C14H22O
206.33
Practically
insoluble or
insoluble
Freely soluble
108 (2 hPa)
–
MS
95 %
1.515–1.521
0.943–0.949
O
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FL-no
JECFA-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility (a)
Solubility in
ethanol (b)
Boiling point, °C(c)
Melting point, °C
ID test
Assay minimum
Refrac. Index (d)
Spec.gravity (e)
07.224 tr-1-(2,6,6-Trimethyl-1-
cyclohexen-1-yl)but-2-en-1-one
3243
2340
23726-91-2
–
–
–
–
–
–
–
–
90 %
–
–
09.305
1409
β-Ionyl acetate  3844
10702
22030-19-9
Liquid
C15H24O2
236.35
Insoluble
Soluble
120 (3 hPa)
–
NMR
92 %
1.474–1.484
0.934–0.944
09.525
1482
Maltyl isobutyrate 3462
10739
65416-14-0
Liquid
C10H12O4
196.20
Insoluble
Soluble
100 (0.01 hPa)
–
IR
96 %
1.493–1.501
1.140–1.153
16.044
1574
Piperitenone oxide 4199
10508
35178-55-3
Solid
C10H14O2
166.22
Soluble
Soluble
–
25
NMR MS
95 %
n.a.
n.a.
n.a.: not applicabile; (-): data not reported
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95 % ethanol, if not otherwise stated.
(c): At 1 013.25 hPa, if not otherwise stated.
(d): At 20 °C, if not otherwise stated.
(e): At 25 °C, if not otherwise stated.
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Summary of Safety Evaluation Applying the Procedure (JECFA 1999, 2001, 2006a, b, 2009a)4.2.
Table 5: Summary of safety evaluation applying the procedure
FL-no
JECFA-no
EU Register name Structural formula EU MSDI (a)
US MSDI
(µg/capita/
day)
Class (b)
Evaluation procedure
path (c)
Outcome on
the named
compound
(d) or (e)
EFSA conclusion on the
named compound
(genotoxicity)
02.106
392
4-(2,2,6-Trimethyl-1-
cyclohexenyl)but-3-en-2-ol
0.73
0.1
Class I
A3: Intake below threshold
(d) Evaluated in FGE.213Rev1,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
07.008
389
β-Ionone 130
100
Class I
A3: Intake below threshold
(d) Evaluated in FGE.213Rev1,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
07.010
399
Methyl-β-ionone 5.4
0.2
Class I
A3: Intake below threshold
(d) Evaluated in FGE.213Rev1,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
07.014
1480
Maltol 3 060
2 898
Class II
A3: Intake above
threshold, A4: Not
endogenous,
A5: Adequate NOAEL exists
(d) Evaluated in FGE.213Rev2,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
07.041 β-Isomethylionone 0.011
Not evaluated by the
JECFA
Evaluated in FGE.213Rev1,
genotoxicity concern could be
ruled out. Can be evaluated
using the Procedure in
FGE.12Rev5.
OH
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FL-no
JECFA-no
EU Register name Structural formula EU MSDI (a)
US MSDI
(µg/capita/
day)
Class (b)
Evaluation procedure
path (c)
Outcome on
the named
compound
(d) or (e)
EFSA conclusion on the
named compound
(genotoxicity)
07.047
1481
Ethyl maltol 1 580
6 692
Class II
A3: Intake above
threshold, A4: Not
endogenous,
A5: Adequate NOAEL exists
(d) Evaluated in FGE.213,
genotoxicity concern could be
ruled out. Can be evaluated
using the Procedure in
FGE.83Rev1. No safety
concern at the estimated level
of intake based on the MSDI
approach.
07.056
418
3-Methylcyclopentan-1,2-
dione
570
710
Class II
A3: Intake above
threshold, A4: Not
endogenous,
A5: Adequate NOAEL exists
(d) Evaluated in FGE.213,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
07.057
419
3-Ethylcyclopentan-1,2-
dione
32
23
Class II
A3: Intake below threshold
(d) Evaluated in FGE.213,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
07.075
420
3,4-Dimethylcyclopentan-
1,2-dione
30
2
Class II
A3: Intake below threshold
(d) Evaluated in FGE.213,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
07.076
421
3,5-Dimethylcyclopentan-
1,2-dione
35
29
Class II
A3: Intake below threshold
(d) Evaluated in FGE.213,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
07.080
425
3-Methylcyclohexan-1,2-
dione
1.3
8
Class II
A3: Intake below threshold
(d) Evaluated in FGE.213,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
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FL-no
JECFA-no
EU Register name Structural formula EU MSDI (a)
US MSDI
(µg/capita/
day)
Class (b)
Evaluation procedure
path (c)
Outcome on
the named
compound
(d) or (e)
EFSA conclusion on the
named compound
(genotoxicity)
07.083
384
β-Damascone 
O 37
10
Class I
B3: Intake below
threshold, B4: Adequate
NOAEL exists
(d) Evaluated in FGE.213Rev1,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
07.089
1398
Nootkatone 130
20
Class II
A3: Intake below threshold
(d) Evaluated in FGE.213Rev1,
genotoxicity concern could be
ruled out. Can be evaluated
using the Procedure in
FGE.87Rev2.
07.108
387
β-Damascenone 73
5
Class I
B3: Intake below
threshold, B4: Adequate
NOAEL exists
(d) Evaluated in FGE.213Rev1,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
07.109
1857
2,6,6-Trimethylcyclohex-2-
en-1,4-dione
50 Class II
No evaluation
Evaluated in FGE.213Rev1,
genotoxicity concern could be
ruled out. Can be evaluated
using the Procedure in
FGE.09Rev5.
07.117
422
3-Ethyl-2-hydroxy-4-
methylcyclopent-2-en-1-
one
ND
0.17
Class II
A3: Intake below threshold
(d) Evaluated in FGE.213,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
07.118
423
5-Ethyl-2-hydroxy-3-
methylcyclopent-2-en-1-
one
ND
0.38
Class II
A3: Intake below threshold
(d) Evaluated in FGE.213,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
07.119
424
2-Hydroxycyclohex-2-en-1-
one
0.049
0.76
Class II
A3: Intake below threshold
(d) Evaluated in FGE.213,
genotoxicity concern could be
ruled out. Evaluated by JECFA
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FL-no
JECFA-no
EU Register name Structural formula EU MSDI (a)
US MSDI
(µg/capita/
day)
Class (b)
Evaluation procedure
path (c)
Outcome on
the named
compound
(d) or (e)
EFSA conclusion on the
named compound
(genotoxicity)
before 2000. No EFSA
consideration required.
07.120
426
2-Hydroxy-3,5,5-
trimethylcyclohex-2-en-1-
one
1.2
2
Class II
A3: Intake below threshold
(d) Evaluated in FGE.213,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
07.127
757
p-Mentha-1,4(8)-dien-3-
one
0.012
0.01
Class II
B3: Intake below
threshold, B4: Adequate
NOAEL exists
(d) Evaluated in FGE.213Rev1 and
FGE.213Rev2, genotoxicity
concern could not be ruled
out. Additional data are
requested.
07.136
1405
4,4a,5,6-Tetrahydro-7-
methylnapthalen-2(3H)-
one
ND
0.04
Class II
A3: Intake below threshold
(d) Evaluated in FGE.213Rev1,
genotoxicity concern could be
ruled out. Can be evaluated
using the Procedure in
FGE.87Rev2.
07.168
2038
2-Hydroxypiperitone 0.0012 Class III
A3: Intake below threshold
(d) Evaluated in FGE.213,
genotoxicity concern could be
ruled out. Can be evaluated
using the Procedure in
FGE.11Rev2. No safety
concern at the estimated level
of intake based on the MSDI
approach.
07.200 4-(2,5,6,6-Tetramethyl-1-
cyclohexenyl)but-3-en-2-
one
0.012 Class I
No evaluation
Evaluated in FGE.213Rev1,
genotoxicity concern could be
ruled out. Can be evaluated
using the Procedure in
FGE.12Rev5.
07.224 tr-1-(2,6,6-Trimethyl-1-
cyclohexen-1-yl)but-2-en-
1-one
100
No evaluation
Evaluated in FGE.213Rev1,
genotoxicity concern could be
ruled out. Can be evaluated
O
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FL-no
JECFA-no
EU Register name Structural formula EU MSDI (a)
US MSDI
(µg/capita/
day)
Class (b)
Evaluation procedure
path (c)
Outcome on
the named
compound
(d) or (e)
EFSA conclusion on the
named compound
(genotoxicity)
using the Procedure in
FGE.12Rev5.
09.305
1409
β-Ionyl acetate ND
9
Class I
A3: Intake below threshold
(d) Evaluated in FGE.213Rev1,
genotoxicity concern could be
ruled out. Can be evaluated
using the Procedure in
FGE.73Rev3. MSDI based on
USA production figure.
09.525
1482
Maltyl isobutyrate 20
38
Class II
A3: Intake below threshold
(d) Evaluated in FGE.213Rev2,
genotoxicity concern could be
ruled out. Evaluated by JECFA
before 2000. No EFSA
consideration required.
16.044
1574
Piperitenone oxide 0.012
0.2
Class III
A3: Intake below threshold
(d) Evaluated in FGE.213,
additional genotoxicity data
required. The substance is not
supported by the Flavour
Industry any longer. No
further evaluation.
ND: no data
(a): EU MSDI: Amount added to food as flavour in (kg/year) x 10E9/(0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365) = µg/capita/day
(b): Thresholds of concern: class I = 1800 µg/person/day, class II = 540 µg/person/day, Class III = 90 µg/person/day
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot
(d): No safety concern based on intake calculated by the MSDI approach of the named compound
(e): Data must be available on the substance or closely related substances to perform a safety evaluation
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(Q)SAR Predictions on Mutagenicity in Five Models for 22 Ketones from Subgroup 2.74.3.
Table 6: (Q)SAR predictions on mutagenicity for 22 alicyclic ketones from subgroup 2.7
FL-no
JECFA-no
EU Register name Structural formula (a) ISS Local
Model
Ames Test
TA100 (b)
MultiCASE
Ames test (c)
MultiCASE
Mouse
lymphoma
test (d)
MultiCASE
Chromosomal
aberration
test in CHO (e)
MultiCASE
Chromosomal
aberration
test in CHL (f)
07.008
389
β-Ionone NEG NEG NEG NEG EQU
07.200 4-(2,5,6,6-Tetramethyl-1-
cyclohexenyl)but-3-en-2-one
NEG NEG NEG NEG EQU
07.010
399
Methyl-β-ionone NEG NEG OD OD EQU
07.041 β-Isomethylionone NEG EQU NEG NEG NEG
07.083
384
β-Damascone 
O OD NEG OD OD EQU
07.108
387
β-Damascenone OD NEG OD OD EQU
07.109 2,6,6-Trimethylcyclohex-2-en-1,4-
dione
OD NEG OD NEG EQU
07.117
422
3-Ethyl-2-hydroxy-4-
methylcyclopent-2-en-1-one
OD NEG NEG OD NEG
O
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FL-no
JECFA-no
EU Register name Structural formula (a) ISS Local
Model
Ames Test
TA100 (b)
MultiCASE
Ames test (c)
MultiCASE
Mouse
lymphoma
test (d)
MultiCASE
Chromosomal
aberration
test in CHO (e)
MultiCASE
Chromosomal
aberration
test in CHL (f)
07.118
423
5-Ethyl-2-hydroxy-3-
methylcyclopent-2-en-1-one
OD NEG NEG NEG NEG
07.119
424
2-Hydroxycyclohex-2-en-1-one OD OD NEG OD NEG
07.120
426
2-Hydroxy-3,5,5-
trimethylcyclohex-2-en-1-one
OD NEG NEG OD NEG
07.014
1480
Maltol OD OD NEG OD POS
07.047
1481
Ethyl maltol OD OD NEG OD POS
07.056
418
3-Methylcyclopentan-1,2-dione OD NEG NEG OD NEG
07.057
419
3-Ethylcyclopentan-1,2-dione OD NEG NEG OD NEG
07.089
1398
Nootkatone OD NEG NEG NEG POS
07.127
757
p-Mentha-1,4(8)-dien-3-one OD NEG OD NEG NEG
07.136
1405
4,4a,5,6-Tetrahydro-7-
methylnapthalen-2(3H)-one
OD NEG NEG NEG OD
O
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FL-no
JECFA-no
EU Register name Structural formula (a) ISS Local
Model
Ames Test
TA100 (b)
MultiCASE
Ames test (c)
MultiCASE
Mouse
lymphoma
test (d)
MultiCASE
Chromosomal
aberration
test in CHO (e)
MultiCASE
Chromosomal
aberration
test in CHL (f)
07.168
-
2-Hydroxypiperitone OD NEG NEG NEG NEG
07.075
420
3,4-Dimethylcyclopentan-1,2-
dione
OD NEG NEG OD NEG
07.076
421
3,5-Dimethylcyclopentan-1,2-
dione
OD NEG NEG NEG NEG
07.080
425
3-Methylcyclohexan-1,2-dione OD NEG NEG OD NEG
OD, out of applicability domain: not matching the range of conditions where a reliable prediction can be obtained in this model. These conditions may be physicochemical, structural, biological etc.
(a): Structure group 2.7: α,β-unsaturated ketones.
(b): Local model on aldehydes and ketones, Ames TA100. (NEG: Negative; POS: Positive; OD*: out of domain).
(c): MultiCASE Ames test (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal).
(d): MultiCASE Mouse Lymphona test (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal).
(e): MultiCASE Chromosomal aberration in CHO (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal).
(f): MultiCASE Chromosomal aberration in CHL (OD*: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal).
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Genotoxicity data (in vitro) considered by the Panel in FGE.2134.4.
Table 7: Genotoxicity (in vitro)
Chemical name
[FL-no]
Test system Test object Concentration Reported
result
Reference Comments (d)
β-Ionone [07.008] Gene mutation
(preincubation)
S. typhimurium TA98,
TA100, TA1535, TA1537
1–180 µg/plate Negative (a) Mortelmans
et al., 1986
Valid.
Gene mutation S. typhimurium TA98,
TA100, TA1535, TA1537
3 mmol/plate Negative (a) Florin et al.,
1980
Insufficient validity (spot test,
not according to OECD
guideline, methods and results
insufficiently reported).
3-Methylcyclopentan-
1,2-dione [07.056]
Reverse mutation S. typhimurium TA1535 10 000 µg/plate Negative (b) Heck et al.,
1989
Validity cannot be evaluated
(result not reported in detail).
Unscheduled DNA
synthesis
Rat hepatocytes 500 µg/plate Negative (b) Heck et al.,
1989
Validity cannot be evaluated
(result not reported in detail).
Maltol [07.014] Reverse mutation S. typhimurium TA100 4.44 µmol/plate
(560 µg/plate)
Negative (c) Kim et al.,
1987
Insufficient validity (only one
concentration was tested with
only one bacterial strain
without metabolic activation).
The main purpose of the study
was to investigate
antimutagenic effects.
Reverse mutation S. typhimurium TA98 and
TA100
Up to 3 mg/plate
(3 000 µg/plate)
Positive (a) Bjeldanes
and Chew,
1979
Valid.
Reverse mutation S. typhimurium TA92,
TA98, TA100 and TA104
1.5 to 11 μmol/plate
(189 to 1 387 µg/plate)
Negative Gava et al.,
1989
Limited validity (data not
reported in detail).
Reverse mutation S. typhimurium TA1535,
TA98, TA100 and TA1537
33 to 10 000 µg/plate Positive (b) Mortelmans
et al., 1986
Valid.
Reverse mutation S. typhimurium TA97 and
TA102
0.1, 0.5, 1, 5, or
10 mg/plate (100, 500,
1 000, 5 000, or
10 000 µg/plate)
Weak Positive (a) Fujita et al.,
1992
Result is considered equivocal.
Limited validity (the use of
only two strains is not
according to OECD guideline).
DNA damage (SOS
Chromotest)
Escherichia coli PQ37 5 mM (631 µg/ml) Negative Ohshima et
al., 1989
The test system used is
considered inappropriate, due
to insufficient validity.
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Chemical name
[FL-no]
Test system Test object Concentration Reported
result
Reference Comments (d)
Sister chromatid
exchange
Chinese hamster ovary
cells
Up to 1.5 µmol/ml
(12.6 to 189 µg/ml)
Positive (c) Gava et al.,
1989
Validity cannot be evaluated
(insufficiently reported:
number of cells analysed not
reported. Statistical test used
not reported). SCEs were
reported as SCE per
chromosome. Effect was less
than twofold compared to
control.
Sister chromatid
exchange
Human lymphocytes Up to 1.0 mM
(126.11 µg/ml)
Positive Jansson et
al., 1986
Validity cannot be evaluated.
Relevance of test system for
the evaluation of genotoxicity
uncertain.
Ethyl maltol [07.047] Reverse mutation S. typhimurium TA 1535,
TA1537, TA1538, TA98 and
TA100
5 concentrations up to
cytotoxicity, or max.
3 600 µg/plate
Negative (a) Wild et al.,
1983
Limited validity (result not
reported in details, no TA102
or E. Coli).
Reverse mutation S. typhimurium TA98 and
TA100
Up to 2 mg/plate
(2 000 µg/plate)
Positive (a) Bjeldanes
and Chew,
1979
Valid.
(a): With and without metabolic activation
(b): With metabolic activation
(c): Without metabolic activation
(d): Validity of genotoxicity studies:
• Valid
• Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and/or limited documentation)
• Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system)
• Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided).
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Genotoxicity data (in vivo) considered by the Panel in FGE.2134.5.
Table 8: Genotoxicity (in vivo)
Chemical name
[FL-no]
Test system Test object Route Dose Result Reference Comments (a)
Maltol [07.014] Micronucleus formation ddY Mouse bone
marrow cells
Intraperitoneal 125, 250, or 500 mg/kg Positive Hayashi et al.,
1988
Valid. The induction of
micronuclei was up to
about 10-fold compared
with control
Sex-linked Recessive
Lethal Mutation
Drosophila
melanogaster
Feed 6 000 ppm
(6000 µg/ml)
Equivocal Zimmering et al.,
1989
Limited validity (only one
exposure level tested).
Test system considered of
limited relevance.
Sex-linked recessive
lethal mutation
Drosophila
melanogaster
Feed 10 000 ppm
(10 000 µg/ml)
Negative Mason et al.,
1992
Valid, however, test
system considered of
limited relevance.
Sex-linked recessive
lethal mutation
Drosophila
melanogaster
Injection 0.2 – 0.3 µl,
10 000 ppm
(10 000 µg/ml)
Negative Mason et al.,
1992
Valid, however, test
system considered of
limited relevance.
Ethyl maltol
[07.047]
Micronucleus formation NMRI Mouse bone
marrow cells
Intraperitoneal 420, 700, or 980 mg/kg Negative Wild et al., 1983 Limited validity (injected
twice; only analysis at one
time point; no PCE/NCE
ratio reported).
Micronucleus formation NMRI mouse
bone marrow cells
Intraperitoneal 980 mg/kg Negative Wild et al., 1983 Limited validity (single
injection, analysis at three
time points, no PCE/NCE
ratio reported).
Sex-linked recessive
lethal mutation (Basc
test)
Drosophila
melanogaster
Feed 14, 25 or 50 mM Negative Wild et al., 1983 Limited validity (limited
reporting, test system
considered of limited
relevance).
(a): Validity of genotoxicity studies:
• Valid
• Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and/or limited documentation)
• Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system)
• Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too few experimental details provided)
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Carcinogenicity studies considered by the Panel in FGE.2134.6.
Table 9: Carcinogenicity studies
Chemical name
[FL-no]
Species; Sex
No./Group
Route Dose levels Duration Results Reference Comments (a)
Ethyl maltol
[07.047]
Rats; Male,
Female
25/sex/group
Diet 0, 50, 100 and
200 mg/kg
bw/day
2 years Males: No increase in
tumour incidences
Females: No increase
in tumour incidences
Gralla et al., 1969 Valid. The study was performed
before the introduction of OECD
guidelines but is, however,
considered valid. The NOAEL was
200 mg/kg bw/day, the highest
dose tested
3-Ethylcyclopentan-
1,2-dione
[07.057]
Rats; Male,
Female
50/sex/group
Diet 0, 30, 80 and
200 mg/kg
bw/day
2 years Males: No increase in
tumour incidences
Females: No increase
in tumour incidences
King et al., 1979 Valid. The study was performed
before the introduction of OECD
guidelines but is, however,
considered valid. The NOAEL was
200 mg/kg bw/day, the highest
dose tested
(a): Validity of genotoxicity studies:
• Valid
• Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and/or limited documentation)
• Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system)
• Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too few experimental details provided)
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Genotoxicity data (in vitro) considered by the Panel in FGE.213Rev1 and FGE.213Rev24.7.
Table 10: Summary of additional in vitro genotoxicity data for FGE.213Rev1
Chemical name
[FL-no]
Test system
in vitro
Test object Concentrations of
substance and test
conditions
Result Reference Comments
β-Ionone  
[07.008]
Reverse
mutation
S. typhimurium TA98,
TA100, TA102, TA1535
and TA1537
0.32–5000 µg/plate
(a, b)
Negative Ballantyne,
2011
Evidence of toxicity was observed in all strains at
concentrations of 1000 µg/plate and greater in the
absence and in the presence of S9-mix. Study
design complied with current recommendations.
Acceptable top concentration was achieved.
S. typhimurium TA98,
TA100, TA102, TA1535
and TA1537
10.24–1000 µg/plate
(b, d) or (c, e)
Negative Evidence of toxicity was observed in all strains at
1 000 µg/plate in the absence and presence of S9-
mix, and in most cases these toxic effects also
extended down to concentrations of 160 or
400 µg/plate. Study design complied with current
recommendations.
Micronucleus
assay
Human peripheral
blood lymphocytes
30–60 µg/ml (d, f)
80–120 µg/ml (e, f)
5–17.5 µg/ml (d, g)
Negative Stone, 2011a The top concentrations induced 50–60 % toxicity.
The MNBN cell frequencies in all treated cultures
fell within the normal range. Study design
complies with OECD Guideline 487.
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Chemical name
[FL-no]
Test system
in vitro
Test object Concentrations of
substance and test
conditions
Result Reference Comments
Maltol
[07.014]
Reverse
mutation
S. typhimurium TA98,
TA100 and TA102,
TA1535 and TA1537
0.32–5000 µg/plate (a,
b)
Negative Ballantyne,
2012
Evidence of toxicity was observed in TA102 at
concentrations of 1000 and 5000 µg/plate in the
absence of S9-mix and at concentrations of
200 µg/plate and greater in the presence of S9-
mix. Study design complied with current
recommendations. Acceptable top concentration
was achieved.
S. typhimurium TA98,
TA100, TA1535
and TA1537
51.2–5000 µg/plate
(b, d) or (c, e)
Negative Toxicity was observed at 5000 µg/plate in strain
TA100 only in the presence of S9-mix. Study
design complied with current recommendations.
Acceptable top concentration was achieved.
S. typhimurium TA102 20.48–5000 µg/plate
(b, d) or (c, e)
Negative Evidence of toxicity was observed at
5 000 µg/plate in the absence and presence of S9-
mix. Study design complied with current
recommendations. Acceptable top concentration
was achieved.
Micronucleus
assay
Human peripheral
blood lymphocytes
400–1262 µg/ml (d, f)
400–1262 µg/ml (e, f)
125–300 µg/ml (d, g)
Equivocal
Positive
Negative
Whitwell, 2012 The top concentrations in the 3 + 21 hours
treatments in the absence and presence of S9-mix
induced, respectively, 24 % and 19 % of toxicity.
The top concentration in the 24 + 0 hours
treatment in the absence of S9-mix induced 57 %
toxicity. There was evidence of micronuclei
induction when tested for 3 + 21 hours in the
presence of S9-mix, while in absence of S9-mix
the data were considered equivocal. However, no
induction of micronuclei was observed in the
continuous exposure test. Study design complies
with OECD Guideline 487.
Chromosomal
aberration test
CHL cells 25, 50, 75 µg/ml
(d, g) or (d, h)
Positive Ishidate, 1988 Structural chromosomal aberrations were
observed at the 2 highest concentrations tested.
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Chemical name
[FL-no]
Test system
in vitro
Test object Concentrations of
substance and test
conditions
Result Reference Comments
β-Damascone 
[07.083]
Reverse
mutation
S. typhimurium TA98,
TA100, TA1535,
TA1537 and TA102
0.32–5000 µg/plate
(a, b)
Negative Bowen, 2011b Toxicity was observed at 1 000 and/or
5 000 µg/plate across all strains in the absence
and presence of S9-mix; no clear evidence of
toxicity in TA100 in the presence of S9-mix. No
statistically significant increase in revertant
numbers was seen at any concentration, either in
the presence or absence of S9-mix.
S. typhimurium,
TA1535, TA1537 and
TA102
S. typhimurium TA98,
TA100
78.13–2500 µg/plate
(b, d) or (c, e)
156.3–5000 µg/plate
(b, d) or (c, e)
Negative
Negative
Evidence of toxicity was observed at the highest
three or four concentrations across all strains in
the absence and presence of S9-mix. No
statistically significant increase in revertant
numbers was seen at any concentration, either in
the presence or absence of S9-mix
S. typhimurium TA98 19.3–1250 µg/plate
(c, e)
Negative Evidence of toxicity was observed at the highest
four concentrations in strain TA98 in the presence
of S9-mix. No statistically significant increase in
revertant numbers was seen at any concentration,
in the presence of S9-mix.
Micronucleus
assay
Human peripheral
blood lymphocytes
8–22 µg/ml (d, f)
12–18 µg/ml (e, f)
6–9 µg/ml (d, g)
Equivocal(d, f)
Positive (e, f)
Equivocal(d, g)
Stone, 2012 Positive result was obtained in the 3 + 21 hour
treatment in the presence of S9-mix. Study design
complies with OECD Guideline 487.
Nootkatone
[07.089]
Reverse
mutation
S. typhimurium TA98,
TA100, TA1535,
TA1537 and TA102
0.5–50 µg/plate (b, d)
1.5.5–150 µg/plate (b,
e)
0.5–50 µg/plate (b, d)
0.5–150 µg/plate (c, e)
Negative Marzin, 1998 Evidence of toxicity was observed at 50 µg/plate
in all strains in the absence of S9-mix and at
150 µg/plate in all strains in the presence of S9-
mix. Study design complied with current
recommendations. Acceptable top concentration
was achieved.
Micronucleus
assay
Human peripheral
blood lymphocytes
50–80 µg/ml (d, f)
160–185 µg/ml (e, f)
10–24 µg/ml (d, g)
Negative Stone, 2011b The top concentrations in all parts of the study
induced >50 % toxicity. The MNBN cell
frequencies in all treated cultures fell within the
normal range. Study design complies with OECD
Guideline 487.
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Chemical name
[FL-no]
Test system
in vitro
Test object Concentrations of
substance and test
conditions
Result Reference Comments
2,6,6-
Trimethylcycloh
ex-2-en-1,4-
dione
[07.109]
Reverse
mutation
S. typhimurium TA98,
TA100, TA1535,
TA1537 and TA102
0.32–5000 µg/plate (a,
b)
Negative Bowen, 2011a Evidence of toxicity was observed at 1000 and/or
5000 µg/plate in strains TA102 and TA1535 in the
presence of S9-mix. Study design complied with
current recommendations. Acceptable top
concentration was achieved.
Reverse
mutation
S. typhimurium TA98,
TA100, TA1535,
TA1537 and TA102
156.3–5000 µg/plate
(b, d) or (c, e)
Negative Evidence of toxicity was observed in TA102 at
2500 and 5000 µg/plate. Study design complied
with current recommendations. Acceptable top
concentration was achieved.
Micronucleus
Assay
Human peripheral
blood lymphocytes
500–1522 µg/ml (d, f)
1000–1522 µg/ml (e, f)
300–550 µg/ml (d, g)
Negative Lloyd, 2011 The top concentrations in the 3 + 21 hours in the
absence and presence of S9-mix were 10 mM. The
top concentration in the 24 + 0 hours in the
absence of S9-mix induced 57 % toxicity. The
MNBN cell frequencies in all treated cultures fell
within the normal range. Study design complies
with OECD Guideline 487.
(a): With and without S9-mix metabolic activation
(b): Plate incorporation method
(c): Without S9-mix metabolic activation
(d): Pre-incubation method
(e): With S9-mix metabolic activation
(f): 3-hour incubation with a 21-hour recovery period
(g): 24-hour incubation with no recovery period
(h): 48-hour incubation with no recovery period
Flavouring Group Evaluation 213, Revision 2
www.efsa.europa.eu/efsajournal 43 EFSA Journal 2015;13(9):4244
Genotoxicity data (in vivo) considered by the Panel in FGE.213Rev1 and FGE.213Rev24.8.
Table 11: Summary of additional in vivo genotoxicity data submitted for FGE.213Rev1 and FGE.213Rev2
Chemical name
[FL-no] Test system Test object Route Dose Result Reference Comments
Maltol
[07.014]
Micronucleus
assay
Han Wistar
Rat; M
Gavage 70, 350,
700 mg/kg
bw/day (a)
Negative Beevers, 2013a The average MNPCE appearance frequency and
ratio of PCE at all dose levels fell within concurrent
and historical control ranges. However, evidence of
target tissue exposure was inconclusive. The study
was performed in compliance with OECD Guideline
474. A further plasma analysis was performed
(Beevers, 2015) showing the systemic exposure of
animals to maltol. Based on the new bioanalysis,
results of the micronucleus assay were considered
as negative.
Comet assay Han Wistar
rat; M
Gavage Negative Mean percentage tail intensity and mean tail
moment were within historical control range at all
test doses. The study was performed in compliance
with recommendations of the comet and IWGT
workshop, Japanese Centre for the Validation of
Alternative Methods (JaCVAM) and current
literature.
β-Damascone 
[07.083]
Micronucleus
assay
Han Wistar
rat; M
Gavage 125, 250 and
500 mg/kg
bw/day (a)
Negative Beevers,
2013b,c
The average MNPCE appearance frequency and
ratio of PCE at all dose levels fell within concurrent
and historical control ranges. The study was
performed in compliance with OECD Guideline 474.
Comet assay Han Wistar
rat; M
Gavage Negative Mean% tail intensity and mean tail moment were
within historical control range at all test doses. The
study was performed in compliance with
recommendations of the comet and IWGT
workshop, Japanese Centre for the Validation of
Alternative Methods (JaCVAM) and current
literature.
(a): Administered via gavage in 3 doses at times 0, 24 and 45 hours with sacrifice and harvest at 48 hours
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Abbreviations
bw Body Weight
CAS Chemical Abstracts Service
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CHO Chinese Hamster Ovary (cells)
CHL Chinese Hamster Lung (cells)
CoE Council of Europe
EC European Commission
FAO Food and Agriculture Organization of the United Nations
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FISH Fluorescence In Situ Hybridisation
FLAVIS (FL) Flavour Information System (database)
GC–MSD gas chromatography–mass selective detection
GLP Good Laboratory Practice
ID Identity
IOFI International Organization of the Flavor Industry
IR Infrared Spectroscopy
IWGT International Workshops on Genotoxicity Testing
JECFA The Joint FAO/WHO Expert Committee on Food Additives
MN Micronuclei
MNBN MicroNucleated BiNucleate cells
MNPCE Micronucleated Polychromatic Erythrocytes
MS Mass Spectrometry
MSDI Maximised Survey-derived Daily Intake
MTD Maximum Tolerated Dose
NCE NormoChromatic Erythrocytes
NMR Nuclear Magnetic Resonance
No Number
NOEL No Observed Effect Level
NOAEL No Observed Adverse Effect Level
OECD Organisation for Economic Co-operation and Development
PCE Polychromatic Erythrocytes
PHA Phytohaemagglutinin
(Q)SAR (Quantitative) Structure Activity Relationship
SCE Sister Chromatid Exchange
WHO World Health Organization
